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During and after transcription in the nucleus, messenger RNAs (mRNAs) undergo a variety of
processing events before being exported to the cytoplasm through the nuclear pore complex.
mRNA processing and nuclear export require a wide range of protein factors, which interact with
maturing transcripts and each other to form dynamic mRNP complexes. While there are many
core, essential mRNP factors, the pathways governing mRNA maturation are not uniform, and
different transcripts can be associated with mRNP complexes of dramatically different
composition or kinetics. To date though, it has been difficult to study RNP complexes specific to
any single mRNA species, as each transcript is relatively unabundant in the cell, and few robust
techniques exist to specifically purify a particular mRNP for proteomic analysis. We thus sought
to develop a method to isolate mRNPs from a single transcript, allowing us to study the dynamic
RNP compositions of individual mRNA maturation pathways.
To optimize purifications of the protein tags required for RNP isolations, we first generated high
affinity reagents targeting key tags like GFP and mCherry. Instead of traditional antibodies, we
chose to use nanobodies: recombinant single domain derivatives of a heavy chain-only antibody
variant found in camelids. The recombinant nature and small size of nanobodies make them ideal
reagents for affinity isolations. We developed an improved pipeline for the identification of
nanobody repertoires against any antigen of interest, which provided us with 25 nanobodies against

GFP, the most common and robust protein tag in use. This pipeline has also allowed us to develop
nanobodies against a variety of other antigens of biomedical interest.
With the help of optimized reagents, we developed a two-step purification method allowing highly
targeted isolations of mRNPs, starting in a budding yeast model system. In our approach, a single
target transcript is tagged with MS2 hairpin sequences – these hairpins are bound specifically and
with high affinity by the bacteriophage MS2 coat protein (MS2CP). In the first purification step,
a chosen RNP protein known to be associated with a particular mRNA processing step of interest
is Protein A-tagged and affinity isolated. From this material, anti-GFP nanobodies are used in the
second step to isolate the MS2-tagged transcript of interest, through purification of MS2CP-GFP
fusion proteins bound to the tag. This approach is able to efficiently and cleanly isolate a particular
transcript at a chosen step of mRNP maturation. The use of an RNP factor as a separate
purification target both improves overall purity and simplifies analysis by limiting heterogeneity
of the mRNP mixture.
Using this novel method for single mRNP isolations, we have performed a preliminary survey of
transcripts with distinct sequence elements suspected to be associated with unique processing
machinery. Mass spectrometric (MS) analysis of RNPs co-purified with these transcripts revealed
several RNA-specific changes in composition. Most notably, introns from either a house keeping
ACT1 gene or the RPS30b ribosomal protein gene led to dramatically different levels of various
splicing-related proteins. These differences provide mechanistic insight into changes in the
kinetics of spliceosome assembly determined by intron sequence.
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Chapter 1: Introduction
Maturation of mRNP complexes in the nucleus
The development of a cell nucleus that separates genetic information from other cellular processes
was a key evolutionary transition, forcing a multitude of adaptations to allow information from the
nucleus to be transmitted to and expressed in the cytoplasm. Messenger RNAs (mRNAs)
transcribed from DNA in the nucleus must be exported through the nuclear envelope, by way of
the nuclear pore complex (NPC), for subsequent cytoplasmic translation. Within this genetic
information pathway, post-transcriptional processing of RNA is a complex step critical to the
proper propagation and regulation of such genetic information. Beyond the transcription of a
gene’s sequence to RNA, distinct combinations of modifications, splicing events, and interactions
with export and localization factors can be required for normal gene expression. These nuclear
maturation and export processes are mediated through an elaborate, hierarchical network of mRNP
complexes, comprised of dynamically associating RNA processing factors. While many of the
essential processing steps along this pathway have been well-characterized, along with their key
components, many questions remain regarding the timing and ordered assembly of mRNP
complexes.

Furthermore, while there is evidence that different mRNA transcripts follow

differential processing and export pathways, the difficulties of analyzing individual subsets of
mRNPs have made identification of alternative mRNA processing machinery difficult. However,
recent methodological advances that, at least potentially, allow high quality isolations of individual
classes of RNP complexes are permitting new insight into the dynamic organization of maturing
mRNPs (Tackett et al., 2005; Gavin et al., 2006; Krogan et al., 2006; Oeffinger et al., 2007).
The basic framework for the biogenesis of a typical mRNP in the model organism Saccharomyces
cerevisiae (budding yeast) is relatively well-established (Figure 1.1). During transcription by
1

Figure 1.1. Overview of mRNP maturation pathway.
transcription, processing, and export are shown.
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From Köhler and Hurt, 2007
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RNA polymerase II, the conserved THO/TREX complex associates with the nascent RNA
transcript, along with splicing factors in the case of intron-containing RNAs (Strasser et al., 2002;
Gornemann et al., 2005; Lacadie and Rosbash, 2005). RNA polymerase II also recruits the enzyme
responsible for adding a 5’ 7-methylguanylate cap, which is then bound by the cap binding
complex (Lewis et al., 1996; Cho et al., 1997; Lewis and Izaurralde, 1997). While yeast TREX is
primarily associated with the transcription machinery, in mammals, TREX is recruited in a splicing
and CBC-dependent manner to the 5’ end of mRNAs (Masuda et al., 2005; Cheng et al., 2006).
Components of the THO/TREX complex are subsequently able to recruit additional RNA-binding
proteins, most notably the yeast Mex67-Mtr2 nuclear export factor, or its TAP-p15 homolog in
metazoans (Gruter et al., 1998; Strasser and Hurt, 2000; Zenklusen et al., 2002; Abruzzi et al.,
2004; Hurt et al., 2004). The Mex67-Mtr2 complex is primarily recruited by Yra1p (metazoan
ALY or REF), an RNA-binding adaptor protein in the TREX complex, and mediates export
through the nuclear pore complex (NPC) by direct interactions with FG-nucleoporins (Segref et
al., 1997; Hurt et al., 2000; Strasser et al., 2000; Zhou et al., 2000). In contrast to typical
karyopherin nuclear export receptors which derive the directionality of their cargo transport from
how they interact with the GTPase Ran, Mex67-mediated export is Ran independent, and
directionality is instead believed to be derived from cytoplasmic mRNP remodeling factors. This
remodeling relies primarily on the ATP-driven RNA helicase activity of Dbp5p, an mRNP
associating enzyme required for the removal of Mex67-Mtr2 (Snay-Hodge et al., 1998; Tseng et
al., 1998; Lund and Guthrie, 2005). Dbp5p is not fully active until stimulated by Gle1p, which is
localized to cytoplasmic NPC filaments, in conjunction with inositol hexakisphosphate (IP 6 ), a
primarily cytosolic signaling small molecule (Alcazar-Roman et al., 2006; Weirich et al., 2006).
According to this model, as the mRNP molecule passes through the NPC, this cytoplasmic
4

remodeling-dependent removal of Mex67-Mtr2 prevents transport back into the nucleus. There is
also evidence that other factors contribute to this export termination, such as the regulated
recruitment of Mex67-Mtr2 by Npl3p, driven by differential nuclear and cytoplasmic protein
phosphorylation. When dephosphorylated in the nucleus, Npl3p can mediate interactions between
mRNA and Mex67; after export however, it is phosphorylated by Sky1p, destabilizing the Mex67
interaction and promoting Npl3p import (Gilbert et al., 2001; Gilbert and Guthrie, 2004). Once in
the cytoplasm, eIF4A and other translation initiation factors are recruited to the mRNP by the
CBC, allowing translation to commence (Lewis and Izaurralde, 1997; Gingras et al., 1999).
Anchoring of a subset of active genes and their transcripts to the NPC is also an important, if
relatively poorly understood element of RNA processing (Casolari et al., 2004; Iglesias and Stutz,
2008; Dieppois and Stutz, 2010). This association appears to involve many different interactions,
such as binding of the SAGA transcription initiation complex by Sus1p, a member of the mRNPand NPC-associated TREX-2 complex, and interactions between other NPC and mRNP proteins,
such as Mex67p and Mlp1p (Galy et al., 2004; Rodriguez-Navarro et al., 2004; Dieppois et al.,
2006). However, how certain genes and their transcripts are selected to undergo anchoring, the
relative timing of this anchoring, and its relationship with various RNA processing events remain
unclear. Several quality control mechanisms are also required for proper mRNA processing. This
task first depends on the nuclear exosome, which is responsible for the sequestration and
degradation of unspliced, unadenylated, or misassembled mRNPs (Bousquet-Antonelli et al.,
2000; Hilleren et al., 2001; Zenklusen et al., 2002; Hieronymus and Silver, 2003). Surveillance of
transcripts to determine which are faulty and thus targeted for degradation also occurs at the
nuclear face of the NPC; there, it seems to chiefly require Mlp1p and Mlp2p, which are involved
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in the retention of unspliced or improperly packaged mRNPs at the nuclear face of the NPC and
away from the NPC’s transport mechanism (Galy et al., 2004; Vinciguerra et al., 2005).
While most studies of mRNP maturation have taken a ground-up approach focusing on individual
processing steps, there has been increasing interest in the characterization of the broader
interactome of maturing RNP particles. Several proteomic studies have begun to comprehensively
identify the factors comprising these dynamic complexes, revealing novel RNP binding proteins
(Gavin et al., 2002; Gavin et al., 2006; Krogan et al., 2006; Oeffinger et al., 2007). However, as
these studies have typically relied on the isolation of tagged RNP proteins rather than individual
species of RNA, it has been difficult to survey anything other than mixtures of many different
types of RNPs associating with a highly heterogeneous RNA population. Furthermore, while these
types of pullouts have revealed discrete subsets of proteins dynamically interacting with and
processing maturing RNA, many questions remain about the timing and order of assembly of such
subcomplexes.
Alternative mRNP maturation pathways
There has been an increasing amount of evidence that certain mRNA processing factors associate
preferentially with different subsets of mRNAs, indicating that there is not a single universal
mRNP maturation pathway (Hieronymus and Silver, 2003; Kim Guisbert et al., 2005; Hogan et
al., 2008; Tuck and Tollervey, 2013; Baejen et al., 2014). This seems to be in contrast to other
classes of RNA, such as tRNAs, rRNAs, or miRNAs, which may have more defined processing
mechanisms, consistent with their less variable structures (Venema and Tollervey, 1999; Kohler
and Hurt, 2007). In addition to obvious differences such as the presence or absence of introns
affecting interactions with splicing machinery, other more central RNP-binding proteins, such as
Npl3p, display different binding preferences to different types of pre-mRNAs (Kim Guisbert et
6

al., 2005; Kress et al., 2008). Even Mex67-Mtr2 recruitment, central to mRNA export, can occur
through different adaptor proteins in different transcripts, including Npl3p and the shuttling mRNA
binding protein Nab2p, in addition to the canonical TREX proteins Yra1p and Sub2p (Gilbert and
Guthrie, 2004; Iglesias et al., 2010). Certain transcripts may additionally require another export
receptor, Crm1p, for proper nuclear export (Gallouzi and Steitz, 2001; Dong et al., 2007).
A variety of transcript-specific RNP interactions have also been identified that depend on
sequences in the 3’ UTR. One of the most well-studied examples is the 3’ UTR of the ASH1
transcript in budding yeast. This gene encodes a transcription factor involved in mating type
switching of daughter cells, and its mRNA localizes to the yeast bud during cell division (Bobola
et al., 1996; Jansen et al., 1996). This localization is mediated by the interaction of She2p with
sequence elements in the 3’ UTR – She2p then recruits She3p and Myo4p, which transports the
mRNA to the bud along actin filaments. This localization activity relies solely on stem-loop
sequence elements in the transcript, which directly encode the alternative cytoplasmic transport
through interactions with SHE proteins (Long et al., 2000; Olivier et al., 2005).
Surprisingly, promoter sequences for a number of genes have been implicated in the regulation of
alternative post-transcriptional processing of their mRNA products, independent of the transcribed
RNA sequence. The promoters of several genes have been shown to confer decreased stability of
their mRNA products, including CLB2 and SWI5, whose transcripts become rapidly degraded
during mitosis (Trcek et al., 2011). Several genes, such as RPL30, whose promoters include
sequence elements recognized by the Rap1p transcription factor, also produce mRNAs subject to
rapid degradation in the cytoplasm by the Xrn1 exonuclease (Bregman et al., 2011). This decrease
in stability is encoded solely by the promoter elements recognized by Rap1p, not the transcript
sequence itself. A similar phenomenon was identified in the case of a number of genes responsive
7

to glucose starvation in yeast, such as heat shock genes (Zid and O'Shea, 2014). For a number of
transcripts upregulated during glucose starvation, it was found that promoter sequences alone
encoded divergent fates for these mRNAs in the cytoplasm: either sequestration to foci and
inhibition translation, or diffusion and rapid translation. In all of these cases, the mechanism
allowing the promoter to determine its transcript’s fate remains largely unclear.
Surveys of mRNA pools associated with specific RNP factors
While it appears clear that multiple mRNP maturation pathways exist, it has been difficult to
comprehensively define any single mRNA’s unique assortment of processing factors or
intermediate complexes. The most common approach to this question has been analysis of mRNAs
associated with a particular tagged RNP factor isolated from cells. A number of studies have used
this approach in yeast, surveying co-purifying mRNAs by microarray or RNA-Seq (Hieronymus
and Silver, 2003; Kim Guisbert et al., 2005; Hogan et al., 2008; Tuck and Tollervey, 2013; Baejen
et al., 2014). Fundamentally, these studies used similar straightforward techniques, namely Protein
A tagging and affinity isolation of major RNP proteins, followed by either RNA-seq or microarray
analysis of purified RNA. In some cases, crosslinking was used to allow mapping of proteinbound RNA sites. To address these questions in mammalian cells, a more common approach has
been to identify RNA binding proteins isolated with bulk RNA or synthetic RNA probes, and
correlate RNPs with different transcript sequences (Butter et al., 2009; Castello et al., 2012).
Surveys of this kind have generated a great deal of data, but a few general patterns have been
consistently found in multiple studies, all consistent with the view that mRNAs commonly have
different preferences in their RNP interactions. For instance, different members of the shuttling
hnRNP family, such as Nab2, Npl3, and Hrp1, have strikingly different mRNA specificities.
Ribosomal protein transcripts in particular (in which introns are most common) have a significant
8

preference for Npl3. While Mex67 exhibits general affinity for all mRNAs, its adaptor proteins,
Nab2, Npl3, and Yra1, each have distinct preferences for different groups of mRNAs. These
preferences also exhibit certain patterns; longer transcripts, for instance, are preferentially bound
to Nab2, while shorter ones tend to be preferred by Yra1.
While this transcriptomic approach has produced much insight on overall trends in RNA
preferences of many RNPs, it is inherently limited in its ability to correlate such differences to
higher order mRNP assemblies. That is, any particular RNP factor will likely be purified from a
heterogenous mixture of different complexes, with different overall compositions. Even an mRNP
protein’s direct interactions with RNAs may be influenced by other components in the broader
complex. Such complications could in part be addressed by performing concurrent proteomic
analysis of such RNP purifications, allowing any identified mRNA enrichments to be correlated
to overall complex protein composition. An alternative, however, would be mRNP purifications
designed to specifically isolate a specific RNA transcript. By this approach, the association of an
RNA sequence for any RNP factor could be directly observed in the context of the overall mRNP
complex, as other proteins present can also be detected.
Tools for isolating RNP complexes
A number of labs have made efforts to tag specific RNAs with unique sequences recognized by a
binding partner and adaptable to a pullout system (Bardwell and Wickens, 1990; Hogg and Collins,
2007; Said et al., 2009; Hogg and Goff, 2010; Slobodin and Gerst, 2010). To date, these
methodologies have shown relatively low purity and yield. This has allowed detection of major
cytoplasmic RNA-associated factors, but typically not lower-abundance factors found in the
nucleus. In theory though, this type of system can allow the characterization of copurifying RNP
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complexes by mass spectrometry and other analytical techniques, providing for a more direct study
of an individual RNA processing pathway.
The use of bacteriophage coat proteins in RNA tagging
A variety of different RNA tagging systems have been developed over the years, with various
advantages and disadvantages.

The most common approach has proven to be the use of

bacteriophage coat proteins binding a cognate RNA hairpin, specifically the MS2 and PP7 systems
(Kozak and Nathans, 1972; Bertrand et al., 1998; Lim et al., 2001; Chao et al., 2008). Short 1925 bp RNA hairpins found in these bacteriophages bind with high specificity and affinity (K D ~
4x10-10 M) to their corresponding MS2 or PP7 binding proteins (Figure 1.2a). By fusing these
bacteriophage coat proteins to a tag such as GFP and co-expressing with transcripts genetically
tagged with the corresponding RNA hairpins, GFP can be targeted to nascent transcripts through
the coat protein-hairpin interaction (Figure 1.2b). This technique has been extensively used for
fluorescent visualization of mRNA transcripts in living cells, as well as in tethering proteins to
RNAs in vivo (SenGupta et al., 1996; Bertrand et al., 1998; Rodriguez et al., 2007; Hocine et al.,
2013).
In a few cases, MS2 or PP7 have been used with varying levels of success to purify tagged RNAs
from cells, along with associated RNP proteins. PP7 hairpins, for instance, were used to tag and
purify RNP complexes of 7SK non-coding RNA (ncRNA), an abundant snRNP regulating
transcription (Hogg and Collins, 2007). The yield in this approach was limited to 20-30%
however, and further limited by non-specific contaminants. Related approaches with either PP7
or MS2 have been used to identify abundant factors from a primarily cytoplasmic mRNA pool,
with similar limitations (Said et al., 2009; Hogg and Goff, 2010; Tsai et al., 2011). To date, these
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Figure 1.2. Bacteriophage hairpins and coat proteins. (a) RNA hairpin structures bound by MS2 or
PP7 coat proteins. (b) Binding of GFP-tagged MS2 or PP7 coat proteins as dimers to cognate hairpins.
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techniques have not been applied to the study of lower abundance mRNP factors typically
associated with nuclear mRNAs.
Other bacteriophage proteins have also been successfully used in these approaches. Effective
systems have been developed from the N protein from bacteriophage λ, known as λ N . This protein
recognizes a short RNA hairpin structure, BoxB, with binding activity determined by a 22 amino
acid region that can be independently synthesized or expressed (Franklin, 1985; Baron-Benhamou
et al., 2004; Daigle and Ellenberg, 2007). Similar to MS2 and PP7, this λ N peptide specifically
binds its cognate 15 bp hairpin structure with high affinity, and has been successfully used in RNA
visualization and protein tethering.
Alternative approaches to RNA affinity capture
Beyond the widely-adopted bacteriophage-based systems, alternative RNA purification techniques
have also been attempted, including the use of antisense oligomers complementary to unique RNA
sequences. Immobilized oligomers can potentially recognize complementary RNA sequences in
cell lysate, particularly using synthetic oligomers such as 2’O-methyl-RNA, LNA (locked nucleic
acids), or PNA (peptide nucleic acids), which are able to form more stable hybrid structures with
complementary RNA sequences (Cotten et al., 1991; Kumar et al., 1998; Larsen et al., 1999).
While these types of reagents have been extensively used for various hybridization techniques,
few studies have succeeded in adapting this technology to isolating intact RNPs from target RNA,
and typically only in the case of stable, highly abundant RNA-protein complexes (Grunweller et
al., 2003; Upadhyay et al., 2013). More typically, these types of approaches have been used to
isolate direct RNA-binding proteins under stringent, denaturing conditions (Castello et al., 2012).
This relies on covalent crosslinking between RNAs and interacting proteins, but the conditions
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required for hybridization and washing of the RNAs to complementary oligomers do not allow for
recovery of additional complex components.
Similar techniques have been developed through the use of RNA aptamers, short RNA secondary
structure-forming sequences that are designed to bind to substrates such as streptavidin,
streptomycin, and tobramycin. These aptamers have been used to tag RNAs of interest, allowing
affinity capture by the immobilized ligand (Bachler et al., 1999; Srisawat and Engelke, 2001;
Hartmuth et al., 2002). This technology has been used, for example, to isolate transcripts
containing AU-rich elements (AREs) from HEK293 cells, copurifying major ARE-binding factors
like HuR (Vasudevan and Steitz, 2007). However, this approach has been limited to some degree
by slow kinetics of binding to streptavidin, low yield (~20%), and non-specific binders (Bachler
et al., 1999; Srisawat and Engelke, 2001). Aptamer tags have also been used in complementary
techniques, such as immobilization of in vitro-transcribed RNAs in order to capture RNA binding
proteins from cell lysate (Butter et al., 2009).
Reagents for affinity isolations
The most promising methods for tagging and isolating RNA transcripts have tended to rely on
MS2 or GFP bacteriophage coat proteins fused to GFP or Protein A (Hogg and Goff, 2010;
Oeffinger, 2012). As efficient purification of these fusion proteins is critical for a successful
isolation of their RNA targets, any such technique must rely on high quality reagents to purify
GFP or Protein A.
In the case of common protein tags like GFP, mCherry, FLAG, myc, or HA, the vast majority of
studies make use of high quality commercial antibodies to target the tag, particularly when affinity
isolation is required (Rigaut et al., 1999; Ho et al., 2002; Cristea et al., 2005; Domanski et al.,
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2012). Although monoclonal or polyclonal antibodies remain the primary bait reagents available
for these purposes, they have a variety of limitations that can sometimes prove problematic. They
are large multimeric proteins, at approximately 150 kDa, and this can result in steric hindrances or
limit density when attached to surfaces, such as resins used for immobilization. Furthermore, the
high cost of commercial reagents, limited availability, and batch to batch variation have often
proved problematic for providing the large amounts of consistently high quality affinity capture
reagents needed for such biochemical or proteomic studies (Gingras et al., 2005).
Single domain antibodies
Due to the limitations of traditional IgG antibodies, a number of efforts have been made to generate
alternatives of smaller size, preferably suitable to production as single recombinant proteins. Some
of the earliest and most successful such reagents are synthetic single-chain antibodies, often termed
scFvs, created by tethering variable heavy (V H ) and light (V L ) chains from monoclonal antibodies
(Figure 1.3) (Bird et al., 1988; Huston et al., 1988; Skerra and Pluckthun, 1988). While there have
been many highly successful examples of such scFvs, whose affinities can rival their monoclonal
IgG progenitors, they can also prove problematic in terms of stability (Dumoulin et al., 2002).
Furthermore, development of a traditional scFv first requires generation of a high quality
monoclonal antibody, followed by engineering of a recombinant sequence able to properly fold
into its native V H /V L conformation, making this a labor- and time-intensive process.
The disadvantages of scFvs are largely due to their two-domain structure, so an antibody fragment
containing only a single variable domain is an appealing alternative. However, individual V H or
V L domains are typically not sufficiently stable or soluble on their own, and may not retain high
antigen affinity when unpaired (Ward et al., 1989). A promising answer to this problem came with
the discovery in camels of a novel class of IgG molecules made only of a heavy chain homodimer,
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Figure 1.3. IgG variants and their derivatives. Standard IgG structures contain both heavy
and light chains. Variable regions from both chains must be combined for use as an Fab
fragment or for recombinant expression as a linked scFv. The camelid VHH IgG variant has
only heavy chains. The single variable region can be cloned and expressed independently as
a nanobody.
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lacking any associated light chains (Figure 1.3) (Hamers-Casterman et al., 1993). This unusual
antibody variant, termed V H H, has only been observed in camelid species, including llamas and
alpacas, though an analogous heavy chain-only Ig (IgNAR), has been identified in cartilaginous
fish (Greenberg et al., 1995). The V H H variable region is thus the smallest antigen-binding single
polypeptide chain naturally found in the antibody world (Arbabi-Ghahroudi et al., 1997; Dumoulin
et al., 2002; Harmsen and De Haard, 2007; Romer et al., 2011; Muyldermans, 2013).
As these V H H antibodies retain strong affinity for their antigens, the variable regions responsible
for binding activity can be cloned out and expressed as independent antigen-binding proteins
known as nanobodies (Arbabi-Ghahroudi et al., 1997; Cortez-Retamozo et al., 2004; Harmsen and
De Haard, 2007; Muyldermans, 2013). Unlike monoclonal antibodies or many other antibody
fragments, they can be readily produced in large, soluble amounts in bacterial expression systems
(Arbabi-Ghahroudi et al., 2005; Harmsen and De Haard, 2007). Moreover, nanobodies are usually
extremely stable, can bind antigens with affinities in the nanomolar or sub-nanomolar range, and
are much smaller in size (approximately 15 kDa) than other antibody constructs (Bird et al., 1988;
Skerra and Pluckthun, 1988; Worn and Pluckthun, 2001; Dumoulin et al., 2002; Rothbauer et al.,
2006; Muyldermans et al., 2009).
However, rapid and robust techniques for the isolation of extensive repertoires of high affinity
nanobodies have proven elusive – the labor-intensive nature and poor efficiency of current
approaches have been a major bottleneck for the widespread implementation of these reagents
(Arbabi-Ghahroudi et al., 1997; Rothbauer et al., 2006; Muyldermans, 2013), explaining why
demand for these reagents greatly exceeds supply (Muyldermans, 2013).
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Tools for targeted affinity isolation of single mRNP populations
To allow closer examination of the multitude of likely alternative mRNP processing pathways, we
have aimed to develop techniques and reagents for the isolation and analysis of individual subsets
of mRNPs. This has involved adapting and optimizing the most promising approaches to tagging
and isolating mRNAs and their associated mRNP factors. A key component of these techniques
is highly efficient protein affinity capture reagents, for which we turned to nanobodies. Given the
limitations of existing nanobody development methods, we generated a new pipeline for nanobody
discovery based on a combination of mass spectrometry (MS) and high-throughput sequencing.
This has provided optimized nanobodies for the high efficiency anti-GFP isolations required for
our mRNP purification method. Secondarily, this pipeline has allowed us to generate repertoires
of nanobodies against a variety of additional antigens of biomedical interest.
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Chapter 2: A new pipeline to generate anti-GFP nanobodies
Strategies for identifying high-affinity nanobody clones
Given the importance of highly efficient isolations of GFP for an RNA purification scheme making
use of MS2CP-GFP, we sought optimized reagents targeting this protein tag. As recombinant
nanobodies are among the most efficient tools available for protein affinity isolation, and are not
currently available against GFP in the quantities required, we sought to generate a new repertoire
of anti-GFP nanobody clones.
In order to identify camelid V H H clones that can be expressed as a recombinant nanobody against
an antigen of interest, such sequences must be cloned out and selected from immunized animals.
Traditionally, this has been done by phage display performed with material from llamas (ArbabiGhahroudi et al., 1997; Conrath et al., 2001; Rothbauer et al., 2006; Alvarez-Rueda et al., 2007;
Pardon et al., 2014). In this method, llama lymphocytes are taken from peripheral blood samples,
and a cDNA library is generated from total mRNA. DNA primers against conserved constant
region sequences flanking the V H H region are then used to PCR amplify this variable domain.
These amplicons are then cloned into a vector that expresses them fused to a bacteriophage coat
protein, producing a library that can be transformed into E. coli to release phages displaying V H H
domains on their surface. These phages can then be bound to the immobilized antigen of interest,
and target-specific V H H-expressing phages can be collected after washing. This panning process
is typically repeated multiple times with the enriched phage populations, after which individual
clones can be selected and screened to confirm binding activity.
While this phage display approach has successfully been used to produce nanobodies against a
variety of targets, it has practical disadvantages. It is a time and labor intensive process, often
taking a total of 3-6 months from beginning to end (Pardon et al., 2014). It carries risk of false
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negatives, as V H H sequences may not fold correctly when displayed on a phage surface, as well
as false positives, since increased avidity of multiple displayed proteins on a phage can amplify
apparent binding of weak or non-specific clones. Furthermore, this approach has often only
identified only a few stable, high affinity nanobodies, even for well-behaved protein antigens such
as GFP (Rothbauer et al., 2006). To overcome these limitations, we sought to develop an
orthogonal approach to nanobody discovery that avoids all these issues and allows simpler, more
rapid identification of larger nanobody repertoires. We therefore worked to design a highly
optimized pipeline that allows the rapid production of repertoires of high affinity nanobodies
against selected proteins. This concept is inspired by previous efforts that identified circulating
neutralizing HIV antibodies in humans using MS in conjunction with patient-specific antibody
cDNA databases (Scheid et al., 2011). The approach is thus based on high-throughput DNA
sequencing of a marrow lymphocyte V H H cDNA library from an immunized llama combined with
mass spectrometric (MS) identification of high affinity V H H regions derived from serum of the
same animal.
Strategy for nanobody identification
Our approach to nanobody discovery centers on MS identification of affinity-purified heavy-chain
antibodies isolated from an individual llama, in correlation with a DNA sequence database
generated from the same animal (Figure 2.1). Our approach represents a novel pipeline for
nanobody production where each stage has been highly optimized.
To generate nanobody repertoires of maximal utility, we chose the GFP (green fluorescent protein)
and mCherry tags for our first target antigens, due to their central roles in cell biological studies
(Shaner et al., 2005). GFP is perhaps the most universally used tag, presenting many advantages
over other tags. Most obviously, it permits both localization and interactomic studies in parallel
19

Figure 2.1. Overview of nanobody identification and production pipeline. The example nanobody
structure shown was obtained from PDB 3K1K (Kirchhofer et al., 2010). LC-MS/MS, liquid
chromatography–tandem mass spectrometry.
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(Poser et al., 2008; Hutchins et al., 2010), and many thousands of proteins in many model
organisms have already been tagged with GFP for visualization, at an enormous cost in both
research time and expense. Based on PubMed searches, the Rout and Chait groups have
conservatively estimated that in excess of $1 billion has been spent on GFP-tagged reagents.
Similarly, mCherry is a very widely used red-fluorescing alternative to GFP, often used as its
complement.
Further, while these fluorescent proteins have a broadly similar beta barrel structure, they are
significantly evolutionarily divergent, making for very distinct immunogens (Shagin et al., 2004).
After immunization of individual llamas with these antigens and confirmation of an immune
response, we serially fractionated serum bleeds to obtain exclusively V H H-containing heavy chain
antibodies (Figure 2.2a), taking advantage of the differential specificity of Protein A and Protein
G for V H H versus conventional antibodies (Hamers-Casterman et al., 1993). The V H H-containing
fraction was affinity purified over antigen-coupled resin, washed with MgCl 2 at various
stringencies to remove non-specific and weakly specific binders (Figure 2.2b), and digested with
papain on-resin to cleave away the constant regions and leave behind the desired minimal V H H
variable region fragments from the remaining high-affinity binders. Finally, the antigen-bound
V H H fragments were eluted and separated by SDS-PAGE, allowing the purification of the ~15
kDa V H H fragments away from residual conventional F ab fragments and F c fragments (both ~25
kDa), and undigested antibodies (~50 kDa) (Figure 2.2c). The gel-purified bands were trypsindigested and analyzed by liquid chromatography-MS and MS/MS (with Yinyin Li, B. Chait lab)
(Figure 2.3). We recovered the highest affinity V H H fragments by using the highest stringency
washes, which also decreased the complexity of the eluted sample, aiding MS analysis.
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Figure 2.2. Purification of an antigen-specific V H H fraction. (a) Llama serum fractionated by
successively binding to Protein G and Protein A agarose resin. VHH variant heavy chains were
specifically eluted in pH 4.0 (Protein G) and pH 3.5 (Protein A) buffers. (b) The GFP affinity of
serum VH and VHH IgG was assessed by resistance to high stringency MgCl2 washes. A llama
serum sample was bound to GFP-sepharose resin, which was then serially washed with increasing
MgCl2 concentrations, followed by elutions with 0.1M glycine-HCl, pH 2.5 and boiling SDS. (c)
Pooled VHH fraction was bound to GFP-Sepharose resin, and washed with 3.5 M MgCl2. Bound
IgG was digested on the beads with papain, releasing Fc fragments. The remaining GFP-bound
VHH fragments were eluted with ammonium hydroxide.
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Figure 2.3. VHH peptide identification of mass spectrometry. Tandem mass spectra of identified
peptides (shown boxed), mapped to the CDR regions of three candidate VHH sequences. The
MS-covered regions of these sequences are underlined. Dashed lines indicate overlapping peaks.
MS analysis was performed by Yinyin Li.
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To create an animal-specific antibody sequence database, lymphocyte mRNA samples from
individual immunized llamas were obtained for high-throughput sequencing. Mononuclear cells
were isolated from bone marrow aspirates, enriching for long-lived antibody secreting plasma
cells, which express elevated levels of immunoglobulin RNA (Benner et al., 1981; Dorner and
Radbruch, 2007; Scheid et al., 2011). Importantly, we do not create expression libraries, and thus
remove the need for efficient exogenous expression, folding, and presentation of the clones, and
avoiding issues of codon adaptation incompatibility.
Total RNA from these lymphocytes was reverse transcribed, and a nested PCR was performed to
specifically amplify sequences encoding the V H H variable regions (Rothbauer et al., 2006). This
PCR product was sequenced using high-throughput 454 (GFP) or MiSeq (mCherry), resulting in
∼800,000 and ∼3,000,000 unique reads, respectively. These reads were translated, filtered and
trypsin-digested in silico to create a searchable peptide database for MS analysis (Figure 2.1).
The identification of specific V H H sequences is more challenging than typical proteins, as they
consist in large part of highly conserved framework regions that are less easily distinguished by
MS. Moreover, rather than searching well-established databases, a V H H cDNA database must be
generated for each immunized animal. To deal with both challenges, we developed (with Sarah
Keegan and David Fenyö, NYU) a bioinformatic pipeline that is able to identify the highest
probability matches from a large pool of related V H H sequences (Llama Magic;
http://www.llamamagic.org). In this pipeline, V H H sequences were ranked by a metric based on
MS/MS sequence coverage of complementarity determining region 3 (CDR3, the most diverse
V H H region) as well as CDR1 and CDR2 coverage, total V H H coverage, sequencing counts, mass
spectral counts, and the expectation values of matched peptides. Preliminary attempts to identify
V H H sequences solely by their CDR3 regions revealed that identical CDR3 sequences are
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frequently shared between multiple distinct V H H sequences, with diverse CDR1 and CDR2
sequences. It is possible that this is a result of somatic gene conversion, in which, after V(D)J
recombination, secondary recombination occurs between upstream V gene segments and already
rearranged V(D)J genes (Becker and Knight, 1990; Knight, 1992).

Alternatively, PCR

amplification could possibly produce apparent recombination of this type, if a conserved region
on an incomplete PCR product serves to prime an unrelated sequence, thus fusing two different
V H H sequences.

Our automatic ranking pipeline, coupled with careful manual inspection,

overcame these issues and provided us 44 high-probability hits against GFP, classified as LaG
(Llama antibody against GFP) 1-44, which we subjected to further screening. A smaller subset of
eight clones was similarly chosen for follow up (LaM 1-8) for mCherry.
Codon optimized genes for these hits were synthesized and cloned into a bacterial expression
vector. After expression, lysates were passed over antigen-coupled resin to identify nanobodies
that displayed both robust expression as well as high and specific affinity. From these screens, we
found 25 specific nanobodies against GFP (LaGs) and 6 against mCherry (LaMs). Phylogenetic
analysis of the verified nanobodies revealed substantial sequence diversity among clones (Figure
2.4). While not directly analogous, the high success rate of this single screening step (57-75%) is
favorable in comparison to the final panning and selection steps of phage display, in which batches
of up to 107 clones are screened repeatedly to identify even a few positive clones (ArbabiGhahroudi et al., 1997; Conrath et al., 2001; Rothbauer et al., 2006; Alvarez-Rueda et al., 2007).
The affinity of these nanobodies was further assessed by either surface plasmon resonance (SPR)
or in vitro binding assays with immobilized nanobodies. For the larger repertoire of LaGs, these
experiments revealed a wide range of affinities, with K d s from 0.5 nM to over 20 µM (Table 1),
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Figure 2.4. Phylogenetic analysis of nanobody sequences. (a) LaG and (b) LaM sequences were
aligned, and (c) a phylogenetic tree was generated from LaG sequences, using the Phylogeny.fr
web service.
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Table 1. Characteristics of LaG, LaG Dimer, and LaM proteins. K d values for GFP and mCherry
binding were determined by SPR unless otherwise noted. K d values are also listed for LaG dimers
fused by a glycine-rich peptide linker (three repeats of GGGGS, or G 4 S) or by a 3xFlag linker. For
yeast Nup84-GFP and mammalian RBM7-GFP affinity isolations using LaGs, Coomassie-stained
bands from elutions separated by SDS-PAGE were quantified, and known specific and nonspecific
bands were used to calculate signal-to-noise (S:N) ratios. Bead binding assays were used to
determine affinity for fluorescent proteins, and the table highlights differences in specificity for A.
macrodactyla CFP among LaGs and for DsRed among LaMs. GFP epitopes for LaGs were
determined by NMR and classified into three groups according to their location (I–III). Also shown
are the number of residues identified in the binding site and the site’s calculated accessible surface
area (ASA). MW, molecular weight; nd, not determined; N/A, not applicable.
a

K d determined by bead binding assay.
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RBM7LAP
S:N

Binds
AmCFP
(LaG) /
DsRed (LaM)

GFP
Epitope

No. of
binding site
residues

ASA of
binding site
residues (A2)

Clone ID

MW (Da)

K d (nM)

Nup84
-GFP
S:N

LaG-2

15,919

19a, 16

1.03

0.42

–

III

55

2,204

LaG-3

15,329

25

0.77

1.13

+

nd

nd

nd

LaG-6

15,700

310

0.12

nd

+

nd

nd

nd

LaG-9

16,062

3.5

1.02

1.04

+

I

62

2,551

LaG-10

15,748

97

0.17

nd

+

nd

nd

nd

LaG-12

16,090

56

0.20

nd

+

nd

nd

nd

LaG-14

16,002

1.9

0.84

0.58

+

I

66

2,519

LaG-16

16,306

0.7

1.05

0.92

+

I

60

2,605

LaG-17

15,823

50

0.67

nd

+

I

60

2,543

LaG-19

15,528

24.6a

0.95

1.06

+

II

54

2,404

LaG-21

15,452

7

1.09

nd

+

II

56

2,340

LaG-24

14,763

41

1.05

1.09

–

III2

nd

nd

LaG-26

16,221

2.6

1.00

nd

+

II

53

2,070

LaG-27

15,565

9.5

1.04

nd

+

II

57

2,216

LaG-29

15,449

110

0.31

nd

+

nd

nd

nd

LaG-30

16,159

0.5

1.04

nd

+

nd

nd

nd

LaG-35

16,010

23.5a

0.70

nd

+

nd

nd

nd

LaG-37

16,329

24

0.36

nd

+

nd

nd

nd

LaG-41

15,471

0.9

1.12

0.41

+

II

53

2,091

LaG-42

15,490

600

0.21

nd

+

nd

nd

nd

LaG-43

16,167

11

0.69

nd

+

I

55

2,381

LaG-5

15,589

14,200a

0.11

nd

nd

nd

nd

nd

LaG-8

15,953

20,000a

0.10

nd

nd

nd

nd

nd

LaG-11

16,221

a

22,900

0.10

nd

nd

nd

nd

nd

LaG-18

16,459

3,800a

0.13

nd

nd

nd

nd

nd

30,791

0.036

nd

nd

nd

nd

nd

nd

32,972

0.268

nd

nd

nd

nd

nd

nd

29,956

0.150

nd

nd

nd

nd

nd

nd

LaM-1

15,380

22

N/A

N/A

–

N/A

N/A

N/A

LaM-2

15,151

0.49

N/A

N/A

–

N/A

N/A

N/A

LaM-3

15,196

1.9

N/A

N/A

+

N/A

N/A

N/A

LaM-4

14,866

0.18

N/A

N/A

+

N/A

N/A

N/A

LaM-6

14,428

0.26

N/A

N/A

–

N/A

N/A

N/A

LaM-8

14,666

63

N/A

N/A

–

N/A

N/A

N/A

LaG16G 4 S-2
LaG163xFLAG-2
LaG41G 4 S-2
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and identified 16 nanobodies with very high affinity binding (≤50 nM). The K d s of the six LaMs
were consistently strong, ranging from 0.18 nM to 63 nM (Table 1).
Specificity and efficacy of recombinant nanobodies
We performed a variety of experiments to assess our nanobodies. Affinity isolations were
performed on endogenous GFP- and mCherry-tagged proteins in yeast and human cells. All 25
positive LaGs were used for the isolation of GFP-tagged Nup84, a structural nuclear pore complex
component, in budding yeast (Figure 2.5a) (Brohawn et al., 2009; Fernandez-Martinez et al.,
2012). We plotted each LaG’s observed K d against a quantification of either signal to background
or yield from a Nup84-GFP affinity capture (Figure 2.5c,d and Table 1). Almost all LaGs were
able to pull down detectable amounts of Nup84-GFP and its associated proteins, and many
performed as well or better than either our best affinity-purified polyclonal antibodies (Cristea et
al., 2005), or than the single commercially available GFP-Trap® anti-GFP nanobody (ChromoTek
GmbH), which has a K d of 0.6 nM (Figure 2.5a,f) (Kirchhofer et al., 2010). When determining
depletion of Nup84-GFP by Western blot, LaG-16, for instance, displays slightly higher yields
than GFP-Trap®. Generally speaking, a strong correlation is seen between low K d and both high
signal to background and high yield. This correlation is consistent with the relationship
theoretically predicted for the percentage of the low abundance yeast target proteins bound in
solution (Ghaemmaghami et al., 2003) (Figure 2.5c). Our ability to compare structurally similar
nanobodies raised against a single antigen provides a unique opportunity to demonstrate the
importance of very low K d to high quality antibody performance in this type of application. Even
nanobodies with K d s around 10 nM, typically considered high affinity for an antibody, start
displaying a precipitous decline in affinity purification performance. These findings highlight the
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Figure 2.5. Characterization of V H H IgG and recombinant nanobodies. (a,b) Affinity isolations of
Nup84-GFP from S. cerevisiae (a) or RBM7-GFP from HeLa cells (b) using LaGs, GFP-Trap or
polyclonal anti-GFP llama antibody (PC). Eluted proteins were analyzed by SDS-PAGE followed
by MS. K d values for GFP are listed. MW, molecular weight. ND, not determined. Contaminant
bands are identified by asterisks. aK d taken from published value (Kirchhofer et al., 2010). (c)
Relative yields of affinity-isolated Nup84-GFP protein plotted against LaG in vitro affinities for
GFP (green dots). Theoretical curves of the expected fraction of ligand bound to an immobilized
binding partner at various K d values are shown for three hypothetical ligand concentrations (blue
lines). (d) Signal-to-noise ratio of three Nup84-complex components plotted against each LaG’s
K d . (e) Affinity isolation of mCherry-tagged histone H2B (Htb2) from S. cerevisiae by LaMs or
RFP-Trap. Eluted proteins were analyzed by SDS-PAGE and identified by MS. Breakdown
products of H2B are labeled ΔH2B-mCherry. Asterisk indicates LaM nanobody that leaked during
the affinity-purification procedure. LaM lanes are labeled with the K d for mCherry. (f) Affinity
isolations of yeast Nup84-GFP using the commercial nanobody GFP-Trap, polyclonal anti-GFP
or a LaG-16–LaG-2 dimer with a glycine-rich peptide linker. The complex was isolated at various
time points, and relative yield was determined by quantification of Coomassie-stained bands of
known Nup84-complex components. Data are representative of two experiments (a–b,e) or are
means from two experiments ± s.e.m. (c,d,f).
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importance of ultra-high affinity reagents, such as the nanobodies described here, for proteomic
and interactomic studies.
Affinity capture experiments were also performed on GFP-tagged Rbm7, a component of the
human nuclear exosome, from HeLa cells (Figure 2.5b) (Domanski et al., 2012), yielding
performances comparable to those seen with Nup84-GFP. However, differences in the amount of
contaminants were seen for certain LaGs, notably LaG-41, from purifications in yeast versus HeLa
cells (Figure 2.5a,b). These results underscore how even high affinity reagents can give
unpredictable background in certain cell types, demonstrating the utility of obtaining and testing
large repertoires of such affinity reagents to improve the chances that at least one is likely to be
optimal for any particular application. Similarly, Dynabead-conjugated LaMs were used to isolate
mCherry-tagged histone H2B from yeast (Figure 2.5e). For all six LaMs tested, the core
nucleosome complex was efficiently isolated, demonstrating the affinity and specificity of this
second group of nanobodies. Consistent with the low K d s of all the identified LaMs, the yield and
specificity of all affinity isolations were similarly high. Commercial RFP-Trap® nanobody
(ChromoTek GmbH) was tested in parallel, giving consistently lower yields.
Nanobodies are powerful new tools for fluorescence microscopy, both standard and superresolution(Ries et al., 2012). We therefore tested the effectiveness of a selection of the LaG and
LaM repertoire for immunofluorescence microscopy (Figure 2.6). As target proteins, we first
made use of emGFP-tagged tubulin and mitochondria-targeted emGFP, transiently transfected
into HeLa cells (Dolman et al., 2013). Fixed cells were stained with LaG-16 conjugated to Alexa
Fluor® 568, giving specific and strong staining of GFP-tagged microtubule or mitochondrial
structures respectively, with negligible non-specific staining of untransfected cells (Figure 2.6a,b).
To demonstrate the versatility of these reagents, we also used them for immunofluorescence in a
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Figure 2.6. Efficacy of LaG and LaM nanobodies in immunofluorescence microscopy. (a,b) HeLa
cells transiently transfected with tubulin-EmGFP or an EmGFP-tagged mitochondrial marker (in
green) were fixed and immunostained with LaG-16 conjugated to Alexa Fluor 568 (AF568, in
red). Nuclei were counterstained with DAPI (blue). (c) T. brucei cells expressing EGFP-tagged
Sec13 were mixed 1:1 with wild-type cells, fixed and stained with LaG-16–AF568, with DAPI
counterstaining. (d) An S. cerevisiae strain with mCherry-tagged histone H2B was fixed,
permeabilized and then directly stained with LaM-4 conjugated to Alexa Fluor 488 (AF488). Scale
bars, 10 μm. Images are representative of at least three experiments.
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Trypanosoma brucei strain with eGFP-tagged Sec13. This protein localizes to both the nuclear
pore complex and COPII-coated vesicles, and indeed the AF568-nanobody signal colocalized with
GFP to give the expected nuclear rim and endoplasmic reticulum staining (DeGrasse et al., 2009)
(Figure 2.6c). To determine if our anti-mCherry nanobodies were similarly well-suited for
immunofluorescence microscopy, we conjugated LaM-4 to Alexa Fluor® 488 and stained S.
cerevisiae expressing mCherry-tagged histone H2B; this also showed specific, colocalized nuclear
staining (Figure 2.6d).
We also compared the fluorescence spectra of GFP in the presence or absence of various LaGs to
look for spectral shifts upon binding, as have previously been reported, and observed moderate
increases in fluorescence for several LaGs, with a maximum increase in fluorescence intensity of
approximately 60% (Kirchhofer et al., 2010).
One additional question of specificity we sought to address was the ability of our nanobodies to
recognize other fluorescent homologs of Aequorea victoria GFP and Discosoma mCherry. We
tested the 13 highest affinity LaGs against a variety of fluorescent proteins: eGFP, two YFP
variants, two CFP variants, BFP, mCherry, and DsRed (Figure 2.7a). None of these nanobodies
bound DsRed or mCherry, two Discosoma sp.-derived proteins with low sequence identity to
eGFP (<30%), or TurboYFP, derived from Phialidium sp., which has 53% sequence identity to
eGFP(Matz et al., 1999; Shagin et al., 2004; Shu et al., 2006). All bound standard Aequorea
victoria-derived CFP, YFP, and BFP variants (>96% eGFP identity). Two LaGs did not bind a
moderately divergent (78% eGFP identity) CFP sequence from Aequorea macrodactyla, while all
others did (Xia et al., 2002). These results indicate that while identified LaGs bind specifically to
fluorescent proteins with high identity to eGFP, differential binding activities can be obtained
through selection of variants from other species. Our anti-mCherry LaM nanobodies bound to
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Figure 2.7. Nanobody fluorescent protein binding. (a,b) SDS-PAGE analysis of high-affinity LaGs (a)
or LaMs (b) that were conjugated to magnetic beads and incubated with various recombinant
fluorescent proteins: A. victoria (Av) GFP and its variants CFP, BFP and YFP; a cyan fluorescent
protein derived from A. macrodactyla (Am CFP); a yellow fluorescent protein from Phialidium (Phi
YFP); and mCherry and DsRed from Discosoma (Ds). Structural models were obtained from PDB
1EMA (Av) (Ormo et al., 1996), PDB 4HE4 (Phi) (Pletneva et al., 2013) and PDB 1GGX (Ds) (Wall
et al., 2000); the Am CFP model is a Phyre server prediction (Xia et al., 2002; Kelley and Sternberg,
2009). Gels are representative of at least two experiments.
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mCherry, but not to any form of GFP, YFP, or CFP tested (Figure 2.7b). Interestingly, two LaMs
(LaM-3 and LaM-4) bound to standard DsRed, which has approximately 80% sequence identity
to mCherry. Given the different fluorescent protein affinities observed with the LaG and LaM
nanobodies, including specificity for AmCFP and DsRed, these reagents have diverse potential
uses in differential labeling and affinity capture experiments from cells simultaneously expressing
different fluorescently-tagged proteins.
Mapping of the nanobody epitopes on GFP
We identified the epitopes on GFP recognized by the twelve highest affinity LaGs using chemical
shift perturbation, a well-established nuclear magnetic resonance (NMR) technique (with Ilona
Nudelman). This method allows the mapping of binding sites on a protein by following changes
in its characteristic “fingerprint” spectrum (typically the 15N-1H HSQC) occurring as a result of
adding an unlabeled ligand into a 15N-labeled protein sample (Goldflam et al., 2012).
Because previous studies have already made backbone 15N-1H chemical shift assignments of the
GFPuv variant (Georgescu et al., 2003; Khan et al., 2003) (closely related to standard eGFP with
97% sequence identity), we prepared

15

N-labeled GFPuv, measured its

15

N-1H HSQC spectrum

and obtained chemical shift assignments based on those published (Georgescu et al., 2003; Khan
et al., 2003). We then tested complexes between 12 high affinity LaGs and 15N-labeled GFPuv and
measured their 15N-1H HSQC spectra. For 11 out of the 12 cases, we observed clear and specific
changes in chemical shifts of a large percentage of cross-peaks compared to the 15N-1H HSQC
spectrum of GFPuv alone. In the 12th case, LaG-24, the nanobody did not bind the GFPuv variant.
A chemical shift difference was calculated for all spectra, and residues exhibiting a difference
higher than 0.03 ppm were judged to be in the binding interface (Zuiderweg, 2002; Goldflam et
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al., 2012). All the identified epitopes corresponded to large interfaces comprising more than 50
amino acids, consistent with the high affinity binding observed (Figure 2.8 and Table 1). The
binding epitopes of the nanobodies can be divided into 3 distinct groups. The binding site of group
I, containing 5 nanobodies (LaG-16, LaG-9, LaG-14, LaG-43 and LaG-17) overlaps with the
binding site of group II, also containing 5 nanobodies (LaG-19, LaG-21, LaG-26, LaG-27 and
LaG-41), whereas the two group III nanobodies (LaG-2 and LaG-24) exhibit a binding epitope on
the opposite side of the GFP molecule compared to groups I and II. As a control, we also used this
NMR approach to determine the GFPuv binding site of the commercial GFP-Trap® nanobody, the
structure of whose complex with GFP has been crystallographically determined (PDB ID
3K1K)(Kirchhofer et al., 2010), and showed that the NMR-mapped epitope matched the published
results (Battistutta et al., 2000; Kirchhofer et al., 2010). Comparing the binding epitopes of our
nanobodies with that of GFP-Trap®, groups I and II show little or no overlap with the GFP-Trap®
binding site, while group III, which binds on the same face of GFP, shows significant overlap
(Figure 2.8).
Generalizability of the pipeline
Our optimized pipeline for the production and generation of nanobodies allows for the rapid
generation of a large antibody repertoire against multiple epitopes in a chosen antigen. Notably,
this approach identifies high affinity nanobody sequences directly from animal serum, taking
advantage of the complex selection and maturation processes occurring in the animal’s immune
system, avoiding intermediary expression systems. The pipeline allows for the rapid production of
a comprehensive repertoire of specific high affinity nanobodies for use in the characterization of
target macromolecules, such as the GFP- and mCherry-tagged proteins shown here. The laboratory
effort required after the collection of samples from llamas (50-70 days after initial immunization,
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Figure 2.8. Mapping of nanobody binding epitopes on GFP by NMR. Binding epitopes of the 11
highest-affinity nanobodies on GFPuv are shown in three groups according to their location. For
each nanobody, two opposite sides of GFPuv are shown (via a 180° rotation along a vertical
axis), with the binding site of the respective nanobody colored green. All GFPuv molecules are
represented in space-filling mode and have the same orientation in all panels. Maps below Group
III in the right column show the GFP-Trap nanobody’s binding epitope (top) and GFPuv’s
homodimerization interface (center). For reference, the ribbon diagram at bottom right depicts
secondary structure elements of GFPuv, in the same orientation as other panels. NMR
experiments and analysis were performed by Ilona Nudelman.
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once an immune response is generated) is modest. The direct work required, including IgG
purification (2 days), MS (2 days), cDNA generation and PCR (2 days), and final cloning and
screening (3-6 days), can be performed over approximately 10 days. High-throughput sequencing
and gene synthesis can be readily outsourced (as can animal handling and MS), and depending on
turnaround times, each can typically be carried out in 1-2 weeks. The entire process can take as
little as 4-6 weeks after an immune response is generated, with only standard techniques required
in the primary laboratory. This is faster and more direct than other approaches available, which
often require specialized high-throughput capability. Our approach puts the generation of large
repertoires and quantities of high affinity single chain antibodies into the hands of the average
researcher. Our LaM and LaG reagents, generated against the widely used GFP and mCherry tags,
will be of immediate general use for the affinity isolation and enhanced visualization of these tags.
Applications of anti-GFP nanobodies
For the purposes of proteomics studies, the most immediate application of our highest performing
nanobodies is affinity isolations of GFP-tagged proteins. Our lab has transitioned to anti-GFP
nanobodies for most GFP-based experiments, with results equivalent to or better than those with
polyclonal antibodies. Several collaborations have also led to improved affinity isolations using
these nanobodies, for instance allowing improved analysis of the interactomes of supervillin and
anillin, proteins regulating the actin and myosin cytoskeleton during cytokinesis (Smith et al.,
2013).
We have also worked to develop new techniques using engineered nanobodies, taking advantage
of the flexibility of these recombinant proteins. Specifically, we have mutated the high affinity
LaG16 nanobody to remove both lysines, changing these to arginines instead (Shi et al., 2015).
These residues are located away from the antigen binding interface, and the mutations did not
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significantly affect the affinity or solubility of the nanobody (Figure 2.9). Removing lysines makes
these nanobodies insensitive to commonly used amine-targeting crosslinkers like 1-ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC) or disuccinimidyl suberate (DSS), after chemical
blocking of the amino terminus. Among other applications, crosslinking protein complexes with
these types of reagents has emerged as an increasingly useful tool for obtaining structural
information. Crosslinked peptides can be identified by MS, providing information on distances
between crosslinked residues within a protein complex, revealing connectivity and aiding
modeling of protein assemblies when integrated with other experimental data (Walzthoeni et al.,
2013).
By developing nanobodies insensitive to crosslinkers, we were able to isolate complexes of
structural interest and crosslink them on nanobody-conjugated beads. As the complex is not
crosslinked to the immobilized nanobody, it can then be easily eluted for MS analysis identifying
crosslinks (Shi et al., 2015). In comparison to alternative approaches, this is a simpler and more
efficient sample processing approach, allowing effective cross-linking/MS of even small amounts
of endogenous material. As a result, in addition to complexes like the yeast exosome or low
abundance anaphase promoting complex, we were able to dissect the structures of assemblies from
highly limited material, including tissue specific Beclin 1 from mouse liver. Our approach has thus
allowed efficient, streamlined cross-linking analysis of endogenous protein complexes through the
use of an engineered anti-GFP nanobody.
Dimerized nanobodies as ultra-high affinity reagents
Because NMR identified multiple epitopes for the 12 LaGs we characterized, we engineered
heterodimers of LaGs with non-overlapping binding sites on GFP that could potentially bind with
higher affinity, an approach that has been successfully used in various applications to develop high
43

Figure 2.9. Lysineless mutants of anti-GFP nanobodies. (a) Protein sequence alignments of 3K1K
and LaG-16. The lysine residues are highlighted in cyan. CDRs: complementarity determining
regions. CDR1, CDR2 and CDR3 sequences are color coded in blue, pink and orange,
respectively. (b) Localizations of the three lysine residues on the crystal structure of nanobody
PDB 3K1K (Kirchhofer et al., 2010), which were mutated to arginine (R) or glutamine (Q) for the
present work. The lysine residues are presented as red spheres.
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avidity reagents (Neri et al., 1995; Silverman et al., 2005). A LaG16-LaG2 fusion with a flexible
glycine-rich peptide linker (encoding three repeats of GGGGS) showed the highest affinity by
SPR, with a K d of 36 pM. Dimers of other LaGs or with a different linker (a 3xFLAG tag),
displayed K d s in the range of 100-200 pM. We also sought to determine whether the higher affinity
of these dimers could yield faster affinity isolations after conjugation to magnetic beads, compared
to single nanobodies or polyclonal anti-GFP. We therefore performed time courses of yeast
Nup84-GFP isolations and compared the relative yields of known Nup84 complex components.
The LaG16-LaG2 dimer showed higher yields at earlier time points, reaching approximately 80%
of maximum yield after only 5 minutes and 90% after 10 minutes (Figure 2.5f). These picomolar
affinity reagents open the door for increasingly rapid affinity isolations, potentially allowing the
capture of weakly or transiently associated complex components for interactome studies. In
addition, their high avidity would allow for the detection of low abundance antigens, as is required
for many diagnostic applications. As the LaG16-LaG2 dimer is the most effective affinity reagent
we identified, we are now using this construct for the most demanding GFP isolations, such as
those involved in mRNP purifications.
Improvements to the nanobody pipeline
Subsequent to our development of nanobodies against GFP and mCherry, we have made a variety
of improvements to our general nanobody identification pipeline, and have succeeded in
generating repertoires against several new antigens of biomedical interest. A full discussion of
this additional work is included in the Appendix. In brief, we found that eliminating papain
digestion of purified V H H IgG led to significantly less non-specific degradation of many antigens,
and therefore provided much higher yields of material and more reliable MS results. As a
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substitute, we determined that IdeS, a far more specific protease targeting IgG (von PawelRammingen et al., 2002), could efficiently remove Fc fragments from isolated IgG.
A further improvement in the pipeline involved selection of llamas or alpacas more likely to
produce the strong immune response we have found to be important in generating large nanobody
repertoires. By pre-screening sera from candidate animals for activity against standard commercial
vaccines, we determined that we could improve the chances of selecting immuno-responsive
animals for antigen injections (Thompson et al., 2016). As immunization is the most costly step
in antibody generation, this ability to screen out less productive animals early on can significantly
improve the efficiency of our method.
We have also begun to apply these methodological improvements to the identification of new sets
of nanobodies. Beginning with two cancer-associated proteins, CTLA4 (Leach et al., 1996) and
EPHA2 (Oricchio et al., 2011), we have generated nanobodies against multiple novel antigens. By
immunizing llamas with 10 or more antigens at once, it has also been possible to rapidly identify
nanobodies against multiple targets in parallel, with no apparent reduction in efficiency. We are
thus continuing to pursue nanobodies against a multitude of new proteins, including a large set of
nucleoporins implicated in cancer (Simon and Rout, 2014).
Finally, in the process of our investigations, we identified strong affinity between a subset of our
nanobodies and staphylococcal Protein A (PrA). This affinity was independent of CDR sequences,
and appears to be a result of non-canonical binding of PrA to the backbone of certain Fab-like
domains (Frenken et al., 2000). To take advantage of this, we engineered a minimal nanobody
construct with strong PrA affinity, but with no other antigen-binding activity (Fridy et al., 2015).
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This protein, along with an even higher affinity homodimer variant, has proven to be a highly
effective PrA-targeting reagent, able to achieve results as good as the much larger and more
heterogeneous IgG preparations typically used.
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Chapter 3: A method to tag and isolate single mRNP species from cells
Identifying a robust RNA tagging system
As discussed above, a key element of this thesis is the development of an RNP purification
technique capable of isolating a specific population of complexes associated with a single RNA.
Many strategies for genetically tagging and purifying RNAs have been attempted, and we therefore
first sought to compare a number of these established methods and determine the most promising
approach. We began by surveying techniques based on anti-sense oligomers, as well as those
involving bacteriophage coat protein / hairpin systems.
Anti-sense nucleic acids as capture reagents
One of the simplest methods we assessed was the use of immobilized anti-sense oligomers to bind
an exogenous, complementary RNA sequence. If this sequence were accessible in the context of
a native mRNP complex, it should theoretically be able to bind virtually irreversibly to the
antisense oligo by hybridization, allowing efficient capture on resin (Grunweller et al., 2003;
Upadhyay et al., 2013). To assess this method, we designed a unique 18 bp sequence to be added
to transcripts as either a series of repeats, or as a loop in a stem-loop structure, potentially aiding
in the accessibility of the sequence. To maximize the stability of the RNA hybrid, we began with
2’O-methylated RNA as the immobilized oligomer, as this analogue forms significantly more
stable hybrids with RNA than DNA (Inoue et al., 1987). These oligomers were synthesized with
either a biotin or thiol group at the 5’ end, allowing capture by streptavidin magnetic Dynabeads
or covalent conjugation to epoxy-activated Dynabeads, respectively.
To test the binding ability of these immobilized oligomers, we first performed binding tests with
in vitro-transcribed RNA transcripts and synthetic RNA oligomers. Using native buffer conditions
routinely used for our RNP affinity purifications, these early tests showed positive but limited
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RNA binding (Figure 3.1a). Notably, binding activity rapidly decreased as the target RNA length
increased from an 18 bp complementary oligomer. A 110 bp tagged transcript showed very limited
binding, while a similar 350 bp transcript had no detectable binding at all. Presumably, steric
hindrance or interference from RNA secondary structure prevented efficient binding of longer
RNAs in these conditions. Even heating binding reactions to 75°C, which would theoretically
promote RNA denaturation and allow more efficient annealing for capture, did not allow binding
of larger transcripts. Given the difficulties observed in these in vitro binding assays, it was
assumed that this oligomer-based approach would not be readily useful in ex vivo RNP
purifications, given the longer lengths of natural transcripts and the further complications likely in
the presence of cell lysate. We also performed similar in vitro experiments with other types of
nucleic acids to identify any oligomer-specific effects, but alternatives including RNA, DNA, or
PNA all showed comparable results.
Assessing the λ N /BoxB system
The most common approaches to tagging RNAs in cells make use of naturally occurring
bacteriophage coat proteins that bind specifically to a cognate RNA hairpin structure. One
example of this is the bacteriophage λ N protein, which includes a minimally necessary 22 amino
acid peptide region that binds to the 15 nt BoxB hairpin sequence (Franklin, 1985). This small
peptide has high affinity for its target RNA (about 22 nM) and has successfully been used in both
in vitro and in vivo applications to tag or visualize RNA (Austin et al., 2002; Baron-Benhamou et
al., 2004; Daigle and Ellenberg, 2007).
To determine if this system could be used for efficient mRNP affinity isolations, we first
synthesized the λ N peptide and conjugated it to epoxy-activated Dynabeads. This immobilized
peptide was capable of binding in vitro-transcribed RNAs with 4-16 copies of the BoxB hairpin
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Figure 3.1. In vitro RNA binding to anti-sense oligos or BoxB peptide. (a) An 18 bp RNA
oligomer (left), or 110 bp (middle) or 350 bp (right) in vitro-transcribed transcripts were incubated
in excess with Dynabead-immobilized 2’O-methylated RNA oligomers with 18 bp of sequence
complementarity. (b) In vitro-transcribed RNA transcripts with 4, 8, or 16 repeats of a BoxB
hairpin were incubated in excess with Dynabeads coated with λN peptide. In all experiments,
bound RNA was eluted by heating in loading buffer, and run alongside load and flow-through
(FT) samples on TBE-urea gels. RNA was visualized by SYBR gold staining.
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sequence, even at transcript lengths up to 750 bp (Figure 3.1b). While the yield was not
exceptional (<25%), these experiments did show substantially more promise for use in endogenous
RNA isolations than immobilized oligomers, as transcripts of a typical mRNA’s length could be
recovered.
We next attempted to isolate RNA ex vivo, starting by tagging a model Protein A gene with BoxB
hairpins (0, 4, 8, or 16 repeats) on a high copy plasmid, under a strong, constitutive TDH3
promoter, and transforming this into wild-type budding yeast. We then grew and prepared these
cells for affinity isolations according to our lab’s routine cryomilling strategy, and reconstituted
frozen, milled cell material in a mild buffer known to stabilize mRNP complexes and that is
compatible with their affinity capture (Oeffinger et al., 2007). After centrifuging to remove cell
debris, soluble lysate was incubated with Dynabead-conjugated λ N peptide. These beads were
then washed, and bound protein and RNA was eluted with hot LDS or phenol extraction,
respectively. While some nonspecific protein binding was observed in the untagged negative
control, enrichment of specific bands was in fact observed with 8xBoxB- or 16xBoxB-tagged
transcripts (Figure 3.2a). Furthermore, qRT-PCR on input and elution samples revealed specific
recovery of the PrA transcript when a BoxB tag was present. However, the yield of transcript was
found to be at most 0.5%, even in the case of the 16xBoxB tag (Figure 3.2b). Thus, while the
λ N /BoxB system did seem capable of specific mRNP purification, the very low efficiency seen in
these pilot experiments suggested that this would not be an immediately practical approach.
Optimizing direct MS2 and PP7-based RNA isolations from yeast
The most common approach to in vivo RNA visualization and targeting has been the MS2
bacteriophage coat protein system, or its close relative PP7 (Querido and Chartrand, 2008). This
was therefore the most promising methodology for an RNA isolation technique, which we
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Figure 3.2. Affinity capture of BoxB-tagged mRNA from yeast. A Protein A transcript tagged with
0, 4, 8, or 16 repeats of the BoxB hairpin was expressed in yeast. Cells were cryomilled, and
soluble lysate was incubated with Dynabeads conjugated to λN peptide. Dynabeads were washed
and split; protein was eluted with hot SDS and RNA was eluted with hot phenol. (a) Protein
elutions were separated by SDS-PAGE and silver-stained. (b) Levels of Protein A transcript in the
RNA elutions were quantified by qRT-PCR, relative to the total amount in the input lysate.
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investigated extensively. The MS2 and PP7 coat proteins (MS2CP or PP7CP) are both known to
bind their corresponding ~20bp MS2/PP7 stem-loop RNA structures with high affinity (~0.5-1nM)
and specificity (106-fold over other RNA sequences) (Carey et al., 1983; Lim et al., 2001). In vivo,
this has allowed visualization of single RNAs through specific binding of hairpin tags by GFPtagged MS2CP or PP7CP, as well as protein tethering to RNA via these same interactions
(SenGupta et al., 1996; Bertrand et al., 1998; Hocine et al., 2013). To a limited extent, this has also
been used to isolate abundant RNAs and their protein binding partners from cells (Hogg and
Collins, 2007; Tsai et al., 2011). Given a high enough relative concentration of a hairpin-tagged
RNA in cells, MS2CP or PP7CP should theoretically be able to provide a significant enrichment
in a purification.
To assess this approach, we began by co-expressing MS2CP-PrA in yeast with a model transcript
encoding GFP, with or without a tag of 6 MS2 hairpin repeats (6xMS2). We started with a GFP
transcript as a simple, exogenous gene, one encoding an essentially inert protein to allow for
nontoxic overexpression (Heim et al., 1994; Okabe et al., 1997). This is an important concern, as
one of the main barriers to the isolation of single mRNAs is the low abundance of any one
transcript. A number of microarray studies have suggested that transcript copy numbers are
typically 1-2 per cell, going up to a maximum of a few hundred copies for the most highly
expressed genes (Velculescu et al., 1997; Wodicka et al., 1997; Holstege et al., 1998; Arava et al.,
2003). More recent single-cell studies, however, have suggested that true copy numbers may be
as much as an order of magnitude higher, at least for weakly-expressed transcripts (Zenklusen et
al., 2008; Larson et al., 2009). In either case, it can be conservatively estimated that 100 transcripts
per cell may be observed for a strongly expressed gene. Identification of proteins by mass
spectrometry requires a minimum protein concentration of 10-20 fmol present in the complex,
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though in practice amounts in the hundreds of fmol or more are preferred (Geiger et al., 2010).
Our cryolysis technique typically handles ~1.2x1010 yeast cells/g powder, so if a model mRNA
with ~100 copies per cell is selected, an associated protein would be present in a concentration of
~2 pmol/g. Thus, even with losses taken into account, a few grams of grindate should theoretically
be sufficient to reliably detect most complex components.
In studies using similar approaches to directly isolate PrA-tagged RNPs, our lab has demonstrated
the feasibility of isolating very low abundance proteins such as Sac3p, reported to have only a few
hundred copies per cell (Ghaemmaghami et al., 2003; Oeffinger et al., 2007). Furthermore,
expression levels of tagged RNAs can be significantly increased by using strong promoters like
TDH3 (~400 transcripts/cell), and expressing off of high copy 2µ plasmids, which can themselves
have 20-40 of copies per cell, or even 100-200 in some cases (Futcher and Cox, 1984; Lopes et
al., 1989; Velculescu et al., 1997). As the total number of mRNA transcripts per cell is estimated
to be between 15,000 and 60,000, and only makes up about 5% of all RNA transcripts, even this
high level of overexpression should not significantly affect, much less overwhelm, the processing
machinery (Hereford and Rosbash, 1977; Warner, 1999; Zenklusen et al., 2008).
Thus, our initial model transcript target was GFP on a 2µ plasmid (pRS426) under a TDH3
promoter, with or without a 6xMS2 tag (Figure 3.3a). MS2CP-PrA was co-expressed on a
centromeric plasmid (pRS414) under a moderately strong inducible MET3 promoter, and with an
SV40 nuclear localization signal (NLS). This NLS localizes MS2 to the nucleus to allow more
efficient association with nascent transcripts, and has been shown to have no significant effect on
subsequent nucleocytoplasmic transport of bound RNAs (Grunwald and Singer, 2010). Cells coexpressing these MS2CP-PrA and GFP constructs were grown and cryomilled, and we performed
single step affinity purifications of MS2CP-PrA using IgG Dynabeads. With low level MS2CP
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Figure 3.3. Affinity isolation of MS2-tagged RNA using MS2CP-PrA. (a) GFP transcripts with or
without a six MS2 hairpin tag were co-expressed in yeast with an MS2CP-Protein A fusion
protein. MS2CP-PrA was expressed under a MET3 promoter, either repressed (+MET) or
induced (–MET). MS2CP-PrA was purified from cell lysate using Dynabeads coated with rabbit
IgG. (b) Co-isolating mRNP proteins were eluted using ammonium hydroxide, separated by
SDS-PAGE, and stained with Coomassie Blue. IgG heavy chain (HC) and light chain (LC)
leakage is labeled. (c) Indicated bands from a MS2CP-GFP (+MET) purification were excised
and analyzed by MALDI MS. Bands are labeled with the corresponding protein ID.
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expression (MET3 repressed by growth in methionine), a number of protein bands copurified only
in the presence of the tagged transcript, with little background observed in the untagged negative
control (Figure 3.3b,c). By qRT-PCR analysis, 14% of the tagged GFP transcript was found in the
final elution (Figure 3.4a). By contrast, under high level MS2CP expression (no methionine), this
yield went up to 22%, but was also accompanied by a significant increase in protein contaminants
in the untagged control sample (Figures 3.3b and 3.4a). Given potential inefficiencies in the
recovery and quantification of the small amounts of RNA in these elution samples, assessing
depletion of the GFP transcript from input to IgG bead flow-through may be a more accurate
measure of yield; in this case yields could be as high as 30% or 65% with high or low MS2CP
expression, respectively.
To identify the major proteins copurified with the 6xMS2-tagged GFP transcript, we performed
MALDI-MS on the prominent bands specific to that affinity purification (Figure 3.3c). This
identified proteins consistent with expected compositions of a typical RNP population. In addition
to multiple ribosomal proteins, most likely associated with RNAs undergoing translation, Pab1p
was identified, a general polyA RNA binding protein, as well as Nam7p, characteristic of mRNA
surveillance for cytoplasmic nonsense mediated decay (Sheth and Parker, 2006). Thus, the major
proteins identified in these mRNP isolations reflect the most highly abundant factors known to
associate with cytoplasmic mRNAs undergoing translation. This is consistent with reports that up
to 70% of the total mRNA population is cytoplasmic and associated with ribosomes, indicative of
rapid mRNA export and a relatively small pool of nuclear mRNA (Arava et al., 2003).
To determine if the yield and purity of this single-step MS2 purification could be improved, we
also tested a variety of modifications to the above approach. First, we attempted to avoid coexpression of MS2CP-GFP in cells by using recombinant MS2CP immobilized to beads as a bait
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Figure 3.4. qRT-PCR quantification of MS2-tagged transcript recovery. (a) RNA samples from
load, flow-through (FT), and elutions of MS2CP-PrA-purified material (Figure 4.3) were used to
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(b) Relative yields of GFP transcripts tagged with 0-24 repeats of MS2 were determined as in (a),
with low level MS2CP-PrA expression.
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for MS2-tagged transcripts. Alternatively, soluble MS2CP tagged with PrA was mixed with cell
lysate, then purified on IgG Dynabeads. In both cases however, significant nonspecific binding
was observed in negative control samples lacking an MS2-tagged transcript. It is likely that the
relative concentration of M2SCP protein in these conditions was so high that extensive off-target
RNA binding was occurring, expected in extreme cases given MS2CP propensity to bind very
weakly to any RNA (Carey et al., 1983). Furthermore, there did not appear to be a point to which
recombinant MS2CP could be titrated to allow sufficient recovery of specific MS2-associated
material while avoiding excessive background binding of contaminants.

Presumably, co-

expressing MS2CP in cells allows more time for it to associate with tagged mRNAs as they are
transcribed and processed in the nucleus, which makes it possible to use the relatively low levels
of the protein necessary to avoid non-specific binding.
In theory, the MS2 tag’s hairpins are saturated in the higher expression conditions used. Under a
MET3 promoter on a centromeric plasmid (~8 copies per cell), MS2CP could be expected to be
present at approximately 3,200 copies per cell (Newman et al., 2006). Given an abundant
transcript with four MS2 hairpins, at approximately 400 copies in a typical yeast cell of 41 µm3
volume, MS2CP and mRNA concentrations would be 128 nM and 64 nM respectively. Assuming
30% of mRNA and all NLS-containing MS2CP is in the nucleus (~2.5 µm3), nuclear
concentrations could be estimated at 2,100 nM MS2CP and 315 nM RNA (Jorgensen et al., 2007).
With MS2CP binding as a dimer, >99% of MS2 hairpins would be bound, and ~85% of MS2CPGFP would be free. In practice, this led to efficient isolation of tagged RNA, but significant
background binding. Under low MS2CP expression, MET3 repression is predicted to be ~16-fold
lower (Jorgensen et al., 2007), giving a theoretical MS2 hairpin saturation of ~20%, and no
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unbound MS2CP. This is also consistent with our results, with low background but low yield of
tagged mRNA.
As a final comparison, we also attempted equivalent affinity isolations using PP7 coat protein
(PP7CP) and its corresponding PP7 hairpin tag in place of MS2. When either coexpressing
PP7CP-GFP or using recombinant protein as bait, the results with this alternative bacteriophage
system were essentially equivalent to MS2. After assessing the different hairpin types, using
different numbers of hairpins in the RNA tag, we ultimately found that MS2 allowed slightly more
efficient isolations, with an optimal tag length of four hairpin repeats (Figure 3.4b).
Sequential protein-RNA affinity purifications
While the direct purification of 6xMS2-tagged RNA by MS2CP-PrA was successful in the specific
isolation of mRNAs at a yield consistent with past studies (Hogg and Goff, 2010), these
experiments revealed certain inherent difficulties with this one-step approach. Given the much
larger pool of mRNA in the cytoplasm compared to the nucleus, no matter how effective the
isolation of total mRNA, it is likely that analysis of lower abundance nuclear proteins would be
hampered by the far more abundant cytoplasmic mRNP factors. While more sensitive mass
spectrometry is capable of detecting far lower abundance proteins than our initial analysis, the high
complexity of these samples and the far higher abundance of cytoplasmic factors would
nonetheless make robust analysis and quantitative comparison of different samples extremely
difficult.
Additionally, it proved difficult to achieve mRNP purifications at both high yield and high
specificity. While MS2CP expression levels could be titered to achieve specific isolations, RNA
yield in these conditions remained in the 14-30% range. For robust analysis of different mRNPs,
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particularly when the associated protein factors of interest are at relatively low abundance, this
compromise in yield would be a significant hindrance. We believe this is an inherent limitation of
the MS2 system, as MS2CP’s nonspecific affinity for RNA, while very weak, will lead to excessive
off-target binding if MS2CP’s expression level is brought high enough to capture MS2-tagged
RNA at an acceptable yield.
To address the dual concerns of non-specific MS2CP binding and unwanted purification of high
abundance cytoplasmic mRNPs, we incorporated a second purification step into our protocol.
While various orthogonal purifications approaches could potentially help address these issues, we
found the most promising option to be isolating a known PrA-tagged mRNP protein in an initial
purification step, before using GFP-tagged MS2 to isolate the specific mRNA subpopulation of
interest (Figure 3.5). First, this additional purification step provides a significant enrichment in
purity simply by providing an independent, highly efficient enrichment of an mRNP population.
Our lab has successfully used this approach to routinely isolate dozens of tagged mRNPs at high
purity and >90% yield (Oeffinger et al., 2007). Beyond this enhancement of purity, the use of an
mRNP protein as a second tagged target has the additional advantage of allowing the isolation of
mRNP complexes at defined processing stages; as a great deal is known of the basic functions and
associated factors of many nuclear mRNP proteins, it is possible to select a number of such proteins
with distinct, well-established roles in mRNP processing as targets. This allows us to isolate a
chosen subset of the mRNP processing machinery, before using the MS2 tag to purify the specific
mRNA of interest, providing high enrichment at a particular maturation step defined by the tagged
mRNA’s association with a given mRNA processing factor.
As a starting point, for instance, tagged Nab2p can be used to isolate a large pool of transcripts at
steps ranging from transcription to export, but largely excluding the cytoplasmic population
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Figure 3.5. Outline of sequential RNP and MS2 RNA isolation method.
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(Batisse et al., 2009; Schmid et al., 2015). Similarly, Cbp80p would be expected to associate with
virtually all nascent mRNAs, remaining bound up until the first round of translation (Lewis and
Izaurralde, 1997). Conversely, Cdc33/eIF4E, part of the cytoplasmic cap-binding complex, would
pre-enrich for cytoplasmic mRNPs (Gingras et al., 1999; Fortes et al., 2000).
Starting with these general mRNA-binding factors, we performed preliminary sequential
purifications using MS2-tagged mCherry transcript. Like GFP, this fluorescent protein was chosen
for its ease of overexpression and detection. In theory, either the PrA-tagged RNP or MS2CPGFP could be purified first in our method; for practicality, we chose to purify the RNP first, as
IgG is more readily available in large quantities, and the first step must necessarily be done at a
larger scale. Additionally, PrA would be likely to bind anti-GFP antibodies given its general IgG
affinity, making it better to remove this tag first. To allow a second, independent purification, we
also needed a means of releasing bound protein from the first affinity isolation. We chose to do
this by inserting a PreScission protease cleavage site upstream of the C-terminal PrA tag. This
protease (a derivative of the rhinovirus 3C protease) is highly active even at low temperatures,
allowing the RNP protein to be cleaved from the tag and bound IgG resin in under an hour at 4°C
(Cordingley et al., 1989). The released material can then be directly incubated with anti-GFP
Dynabeads, with PrA no longer present. To start with, we coexpressed MS2CP-GFP under an
unrepressed MET3 promoter on a centromeric plasmid, conditions which led to high yield but nonspecific single-step isolation of tagged RNA.
In preliminary pullouts using this sequential method, purifications of transcripts tagged with MS2
isolated significant amounts of protein, with a banding pattern similar to an equivalent single-step
isolation of the corresponding tagged RNP (Figure 3.6). In contrast, negative controls with
untagged transcripts had essentially no associated protein, indicating very little non-specific
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Figure 3.6. Sequential Nab2 RNP and RNA purification of mCherry-4xMS2. mCherry transcripts
with or without a 4xMS2 hairpin tag were co-expressed with MS2CP-GFP in yeast and purified in
two steps with Nab2-PrA and MS2CP-GFP. Samples of PPX protease elutions from IgG beads
(step 1), and flow-throughs (FT) and elutions from anti-GFP beads (step 2) were separated by
SDS-PAGE and stained with Coomassie Blue. RNPs are only co-purified in the presence of the
4xMS2 tag. In parallel, equivalent samples were directly eluted from anti-GFP beads with
ammonium hydroxide and analyzed by MS. RNP protein IDs from that analysis are listed,
categorized according to function.
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binding due to MS2CP. This indicates that even in conditions with saturating levels of MS2CP,
the addition of the PrA purification step essentially eliminates the non-specific binding previously
observed. As we expect the tagged model mCherry transcript to behave as a typical mRNA, it was
not surprising that the final protein isolated appeared generally similar to the mixed RNP
population observed in a single step RNP purification. However, the relative intensities of a
number of bands do in fact appear to differ in the mRNA-specific isolation, and fewer superstoichiometric bands are present, indicating differences in the purified RNP pools, and in particular
less free protein.
Assessing efficiency of sequential isolations
To determine the efficiency of each purification step at the protein level, we did Western blotting
of each tag (PrA and GFP) across the procedure (Figure 3.7). Depending on the cellular abundance
of the PrA-tagged RNP and amount of IgG Dynabeads used, the yield of the PrA isolation was as
high as 90%. Judging from the amount of uncleaved PrA-RNP protein remaining on the IgG
beads, the efficiency of the cleavage step was highly variable from protein to protein, but generally
above 50%. We have observed this type of variability in many protein complexes studied in the
lab, and suspect it to be due to protein-specific differences in the accessibility of the cleavage site,
or other structural influences. Similar variability is found in the propensity of complexes to stick
to the Dynabeads even after tag cleavage, and these issues have shown little dependence on the
isolation conditions used. When following GFP signal, MS2CP-GFP was detected in the IgG bead
elution only when a tagged transcript was used. This protein was then depleted at high efficiency
by anti-GFP Dynabeads. As expected, less than 5% of the total MS2CP-GFP in the lysate was
depleted in the initial PrA purification; this is consistent with the small fraction of total mRNA
predicted to be associated with any one RNP factor, as well as the excess of MS2CP-GFP present
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Figure 3.7. PrA and GFP yield of sequential Nab2-PrA and MS2CP-GFP purification of mCherry4xMS2. Samples from a sequential purification of untagged or 4xMS2-tagged mCherry were
analyzed by Western blot, probing either PrA or GFP. 15 times less material was loaded for PrA
Load and flow-through (FT) samples. More than 80% of Nab2-PrA was recovered in the PrA
purification step, and more than 90% of this was cleaved by PPX, as judged by cleaved vs
uncleaved PrA remaining on beads after protease elution. MS2CP-GFP is recovered after both
purification steps only when the mCherry transcript contains a 4xMS2 tag. Due to both free
MS2CP-GFP and the mCherry-4xMS2 population not associated with Nab2, only a small fraction
of MSCP-GFP is co-purified with Nab2-PrA.
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in these expression conditions. The relative amounts of GFP and total protein obtained in these
purifications were also dependent on the tagged RNP protein used. Consistent with the higher
abundance of cytoplasmic versus nuclear mRNA, Cdc33 isolations had significantly more material
than those of Cbp80 or Nab2.
We also performed MS analysis on the material purified from these initial Nab2, Cbp80, and
Cdc33-based RNA purifications (Figures 3.6 and 3.8). As expected, the proteins identified were
essentially the same as those previously identified from purifications of these RNP factors
themselves (Oeffinger et al., 2007). For Cbp80-based isolations, this includes major RNA binding
proteins like Pab1p and Yra1p, cap complex components Cbp80p and Cbp20p, members of the
THO/TREX complex, and spliceosomal factors. For Cdc33, we identified expected cytoplasmic
factors like members of the cytoplasmic cap (eIF4E and eIF4GA), Pab1p, and translation initiation
factors. For Nab2, we identified Pab1p, a variety of export factors like Yra1p and members of the
TREX-2 complex, as well as a number of nuclear pore complex (NPC) components, consistent
with transcripts actively undergoing export. Additional quantitative analysis would be necessary
to identify transcript-specific RNP factors from these purifications (Chapter 5).
The purity and yield of MS2-tagged transcript was also assessed from these pilot affinity
purifications. Quantitative real-time RT-PCR (qRT-PCR) was also performed on various samples
from these isolations (Figure 3.9a). In the case of Cbp80-PrA purifications, this analysis showed
a recovery of approximately 20% of mCherry transcript in the first purification step, with or
without a tag present. This is broadly consistent with the amount of bulk mRNA expected to be
capped and not undergoing translation. In the second MS2CP-GFP purification step, ~75% of this
material is recovered, only in the presence of the 4xMS2 hairpin tag. Thus, MS2-tagged transcripts
do appear to be efficiently and specifically recovered by this technique. As a control, 18S rRNA
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Figure 3.8. Sequential purifications of mCherry-4xMS2 using Cbp80-PrA or Cdc33-PrA. mCherry
transcripts with or without a 4xMS2 hairpin tag were co-expressed with MS2CP-GFP in yeast and
purified in two steps with Nab2-PrA or Cdc33-PrA and MS2CP-GFP. Final elutions from anti-GFP
beads were separated by SDS-PAGE and stained with Coomassie Blue. In parallel, equivalent
samples were directly eluted from anti-GFP beads with ammonium hydroxide and analyzed by MS.
RNP protein IDs from that analysis are listed, categorized according to function.
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Figure 3.9. RNA yield in sequential Cbp80 and MS2CP-GFP purification of mCherry-4xMS2. (a)
qRT-PCR was performed on RNA samples taken at each purification step in isolations of untagged
or 4xMS2-tagged mCherry transcripts. Primers were used against the mCherry targer sequence,
or 18S rRNA to assess non-specific binding of an abundant RNA contaminant. Transcript levels
were normalized to total input level (1 and 6).
2) and 7) 0-20% depletion of mCherry is observed in the first step purification of Cbp80-PrA
3) and 8) ~20% of mCherry transcript was recovered in native elutions after the first purification
step. This is consistent with the small proportion of mRNA expected to associate with Cbp80,
independent of the MS2 tag. No 18S rRNA is detected in this purification step, consistent with
Cbp80’s specificity for mRNA over rRNA.
4) and 9) After anti-GFP isolation of MS2CP-GFP, the mCherry transcript is strongly depleted
only when 4xMS2-tagged. This reflects MS2CP-GFP’s presence only when bound to the tagged
transcript.
5) and 10) In elutions from anti-GFP beads, no untagged transcript is detected. Tagged mCherry4xMS2 is efficiently recovered from the Cbp80-PrA-associated pool (8).
(b) Northern blots were performed against RNA samples equivalent to (a). Radiolabeled probes
were complementary to either mCherry or 18S rRNA transcripts. Signals are consistent with the
qRT-PCR results.
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Figure 3.10. RNA-seq analysis of total RNA isolated by sequential purification of
mCherry-4xMS2. After sequential purification using the indicated PrA-tagged RNP factor and
MS2CP-GFP, RNA was eluted and directly prepared for RNA-seq on an Illumina HiSeq 2000
system. Reads were categorized as either mCherry-4xMS2, rRNA, or other snRNA or mRNA.
Depending on the tagged RNP used, 50-70% of all RNA recovered was specific to the tagged
mCherry transcript.
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Figure 3.11. Comparing anti-GFP beads in sequential Cdc33-PrA and MS2CP-GFP purifications
of mCherry-4xMS2. Tagged or untagged mCherry transcripts were purified first over IgG
dynabeads (GFP Input), and then over Dynabeads conjugated to either polyclonal anti-GFP
antibodies (Polyclonal), LaG16 nanobody, or the LaG16-LaG2 dimeric nanobody. Protein was
eluted with LDS and visualized by Coomassie Blue staining after SDS-PAGE.
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was also quantified by qRT-PCR, and ~0.02% was ultimately recovered, with only ~0.2% detected
after the first purification step (Figure 3.9a). This is consistent with the divergent pre-rRNA
processing pathway expected for this rRNA, and shows that even highly abundant non-specific
RNAs are not significantly co-isolated in this method. As a further assessment of RNA recovery,
Northern blots were performed probing mCherry and 18S RNA (Figure 3.9b). This recapitulated
the qRT-PCR results, and while some degradation is observed, the majority of the RNA purified
appears intact.
We also assessed the purity of the final RNA pool recovered in these mRNP isolations by RNASeq. This technique allows unbiased quantification of the relative amounts of all transcripts in our
samples by sequencing all RNA present (Wang et al., 2009). By this analysis, we determined that
the mCherry-4xMS2 transcript comprised approximately 60-70% of purified RNA, depending on
the tagged RNP used (Figure 3.10). An additional 5-10% was rRNA, and the remainder was from
low levels of other non-specific RNAs. Given the heterogeneity of the non-specific RNA
contaminants in these pullouts, it is likely that the final RNP content is largely representative of
the highly enriched tagged transcript.
To further optimize the efficiency of the MS2CP-GFP purification step, we transitioned from using
polyclonal anti-GFP antibodies from llama serum for the final GFP-MS2 isolations to our own
anti-GFP nanobodies (Chapter 2). Both LaG-16 nanobody and the LaG16-G4S-LaG2 dimeric
nanobody gave higher yield and lower background in these pullouts, with the dimer performing
best in both regards (Figure 3.11). We are thus using this reagent for all subsequent purifications.
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Chapter 4: Pilot survey of RNPs associated with single mRNAs
A survey of RNA sequence elements associated with unique processing factors
As a pilot study to demonstrate the efficacy of the sequential protein-RNA isolation technique, we
conducted a survey of several transcripts of interest. As a first step, transcripts were based on a
model mCherry sequence, modified in various ways by the introduction of different sequence
elements. This allowed us to use the exogenous mCherry sequence as a control, with no expected
atypical processing in yeast, and easily expressible at high levels with no biological effects (Shu
et al., 2006; Fink et al., 2010; Kafri et al., 2016). This base sequence was then modified with the
addition of other promoters, introns, and 3’ UTR elements (Figure 4.1). Specifically, we studied
introns of different classes, for example comparing those found in highly expressed housekeeping
genes like ACT1 to those of ribosomal proteins like RPS30b, whose transcripts are reported to
have atypical mRNP compositions (Schmid et al., 2012; Tuck and Tollervey, 2013). An additional
interest is comparison of transcripts expressed from promoters with different regulatory
mechanisms, such as those from housekeeping or stress-inducible genes. Multiple promoters have
also been implicated in post-transcriptional regulation of mRNA stability, and the mRNP complex
dynamics involved in these processes are still poorly understood (Bregman et al., 2011; Trcek et
al., 2011; Zid and O'Shea, 2014). We began to assess these questions by adding promoters
implicated in this downstream transcript regulation to our model mCherry transcript. For these
various transcripts of interest, we performed a survey using sequential affinity isolations,
beginning with general RNP factors for initial purification.
Confirming recovery of Ash1 transcript-specific mRNP factors
As a first step in determining whether changes in a model transcript affect the co-isolating mRNP
composition, we tested transcripts with sequence elements understood to be differentially targeted
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Figure 4.1. MS2-tagged constructs used in survey of mRNPs. An mCherry coding sequence was
expressed on a high copy yeast 2µ plasmid under a strong constitutive TDH3 promoter (Mumberg
et al., 1995), or promoters from HSP26 or GLC3 genes (Zid and O'Shea, 2014). A 4xMS2 tag was
inserted immediately following the mCherry stop codon. As modifications, either the 3’UTR
from the ASH1 gene was inserted after the 4xMS2 tag (Bertrand et al., 1998), or intron sequences
from ACT1 or RPS30b were inserted 31 bp into the mCherry sequence.
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by RNP processing machinery. A particularly well-studied example is 3’ UTR region of the Ash1
transcript. Sequence motifs in this UTR recruit She2p and She3p, which target the transcript to
the bud tip after export (Long et al., 2000; Olivier et al., 2005). We therefore added the ASH1 3’
UTR to our model TDH3-driven mCherry gene, with a 4xMS2 tag between the coding sequence
and UTR. The general cap binding protein for nuclear mRNA, Cbp80p, was then used as a PrAtagged first target for sequential affinity isolation (Chapter 3).
As expected, MS analysis of protein purified from these pullouts identified significant amounts of
She2p and She3p, as well as Myo4p, known to be involved in cytoplasmic localization of Ash1
mRNA on actin filaments (Figure 4.2) (Bertrand et al., 1998). Interestingly, we found significant
amounts of two other proteins, Htb2p (histone H2B) and Hir3p, part of a nucleosome assembly
complex that regulates histone gene expression (Prochasson et al., 2005). Hir3p in particular is a
low abundance protein not typically found as a contaminant, but it is unclear what connection
might exist between its chromatin remodeling activity and ASH1 transcription.

If Hir3p

association is confirmed, this connection could be investigated by genetic experiments to assess
changes to ASH1 transcription in HIR3 mutants, as well as more targeted proteomics of the HIR
complex.
Beyond She2p and She3p, there are other factors reported to be involved in Ash1 localization that
were not identified in our purification, notably Loc1p, which stabilizes She2p association, and
Puf6p. This may be due to the different dynamics of these proteins’ interactions with Ash1 RNA;
Loc1p for instance is only bound in the nucleus, and is released upon export through displacement
by She3p (Niedner et al., 2013). As we detect She3p but not Loc1p, it may be that Cbp80passociated Ash1 RNA is highly enriched for the She3p-bound state, presumably due to the rapid
kinetics of Loc1p association and dissociation. Puf6p binds Ash1 RNA independently of She2
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Figure 4.2. Sequential Cbp80-PrA and MS2CP-GFP isolation of mCherry-4xMS2-Ash1 3’UTR
mRNPs. A Coomassie-stained gel of the purification was imaged, and protein identifications
were made by MS on a whole sample purified in parallel as a gel plug. IDs are shown at predicted
molecular weights, and proteins uniquely identifed with the Ash1 3’UTR are shown in bold.
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and is thought to remain bound through export. However, it is also highly enriched in the nucleus,
and may be less abundant in the purified RNP population due to similar kinetic differences as
Loc1p.
Alternatively, it is possible that these proteins are simply less stably associated with the RNA, and
are thus not retained throughout the purification process, or else rely on other ASH1 sequence
elements not present in the UTR used. In this and other cases though, there is evidence that we
are not seeing substantial loss of RNP factors in our isolations. First, previous studies have shown
that certain dynamic mRNP proteins, such as Yra1p, do not exchange between mRNAs under our
typical purification conditions (Oeffinger et al., 2007). Furthermore, our preliminary mRNP
isolations have purified factors suspected to be relatively unstable and dynamic. Intron containing
transcripts, for instance, have co-purified with essentially all expected splicing proteins, including
relatively transitory proteins like those involved in the second step of catalysis, including Slu7p,
Prp16p, and Prp43p (Fabrizio et al., 2009).

However, to confirm that dissociation during

purification is not a complicating factor, we plan to test this by performing isolations at different
time scales, as well as with UV treatment to create RNA-protein crosslinks. By determining if
shorter incubations or UV stabilization significantly affects mRNP composition, we can assess the
stability of our natively purified complexes.
mRNP factors specific to introns
We next performed isolations of a 4xMS2-tagged mCherry transcript containing artificially
inserted introns. First, we inserted an intron from the ACT1 gene, a well-studied, highly expressed
yeast cytoskeletal gene with a 309 nt intron (Gallwitz and Sures, 1980). In comparison to Nab2pbased pullouts with mCherry transcripts lacking an intron, pullouts of the ACT1 intron-containing
mRNA show clear changes in the banding pattern of the co-isolated mRNP complex (Figure 4.3).
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Figure 4.3. Sequential Nab2-PrA and MS2-GFP isolations of mCherry-4xMS2 and
mCherry(Act1 intron)-4xMS2 mRNPs, alongside negative controls from transcripts with
no MS2 tag. Coomassie-stained gels of the purifications were imaged, and protein
identifications were made by MS on directly eluted whole samples prepared in parallel. IDs
are shown at predicted molecular weights.
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Mass spectrometric analysis of protein elutions from these pullouts provided a finer look at these
distinctions. While the intronless mCherry transcript was associated strongly with many nuclear
pore complex components, transcripts containing an intron were instead strongly associated with
numerous spliceosomal factors (Figure 4.3). This difference is likely explained by a change in the
rate-limiting step of the processing of Nab2p-associated mRNA from export to splicing. It is clear
that export of intron-containing mRNAs is dependent on completion of splicing, which seems to
be required for co-transcriptional recruitment of the Yra1p export adapter (Lei and Silver, 2002).
However, the relative kinetics of transcription, splicing, and export in yeast remain somewhat
unclear. While a number of studies have shown that splicing occurs co-transcriptionally, it is
possible that some transcripts with shorter second exons are spliced post-transcriptionally (Kotovic
et al., 2003; Gornemann et al., 2005; Tardiff et al., 2006). There is increasing evidence, though,
that transcriptional pausing occurs in terminal exons, leading to primarily co-transcriptional
splicing in genes, regardless of exon length (Carrillo Oesterreich et al., 2010; Churchman and
Weissman, 2011). Assuming the necessity of splicing for export, this relatively slow process,
reported to be in the range of 60 sec (Tardiff et al., 2006; Alexander et al., 2010), would be
expected to be rate-limiting in comparison to relatively rapid nuclear export (~180 ms) (Grunwald
and Singer, 2010).
As Cbp80p plays a direct role in spliceosome recruitment and is expected to be present in mRNPs
undergoing splicing (Lewis et al., 1996), we performed an equivalent pair of affinity isolations
with Cbp80p used as the initial mRNP target (Figure 4.4). In this case, all major spliceosomal
factors were identified by MS in the presence of an intron, compared to a subset of U1 components
with the intronless transcript. Given Cbp80p’s involvement in early splicing and the persistence
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Figure 4.4. Sequential Cbp80-PrA and MS2-GFP isolations of mCherry-4xMS2
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of the cap complex, it is expected to be associated with the active spliceosome, consistent with the
presence of the full spliceosome in our isolations of intron-containing RNAs (Lewis et al., 1996).
It has been less clear which spliceosomal factors, if any, associate with intronless transcripts. The
U1 snRNP, generally the earliest spliceosome component to bind, is known to recognize the 5’
splice site of introns, and is therefore predicted to be highly enriched on intron-containing
transcripts (Seraphin and Rosbash, 1989; Will and Luhrmann, 2011). Despite this enrichment, U1
components have been found at low but detectable levels on many intronless genes (Kotovic et al.,
2003).

While little has been known of U1 snRNP’s nonspecific mRNA interactions, our

identification of U1 factors on intronless transcripts supports a model in which recognition of true
splice site sequences depends on promiscuous scanning, or transitory binding of all transcripts.
However, it is also conceivable that the mCherry sequence used in these experiments includes
uncharacterized cryptic splice sites, so other transcripts would have to be tested to confirm this
model.
Label free protein quantification by mass spectrometry
While observing the presence or absence of different RNP factors has proved informative in the
case of the clear-cut changes in composition seen with the Ash1 3’ UTR or an intron, it would be
useful to detect changes in the relative abundance of such factors as well. It is likely that important
variations in RNA processing could be associated with several-fold differences in RNP protein
abundance, and identifying even the approximate stoichiometry would be useful in these more
subtle cases.
As a straightforward method for quantifying protein levels both between and within samples, we
pursued label-free MS quantification techniques (with Erica Jacobs, B. Chait lab). This avoids the
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technical difficulties involved in differential stable isotope labeling of all cells to be compared
(Oda et al., 1999; Ong et al., 2002), while retaining sufficient accuracy to identify significant
changes in protein abundances. While many variations of label-free quantification approaches
have been described, it has generally been found that the most reliable methods make use of peak
intensities of three or more peptides from proteins to be quantified (Old et al., 2005; Silva et al.,
2006; Bantscheff et al., 2007; Schwanhausser et al., 2011). This has led to reported accuracies
within 20%, sufficient to detect the multi-fold differences in abundance of most interest to us, and
has been found to be somewhat more accurate than similar spectral counting approaches. While
most accurate in comparing the relative abundance of the same protein in different samples, this
technique has also been successfully used to identify the stoichiometry of different proteins within
a single complex (Smits et al., 2013; Taylor et al., 2013). This is a further advantage of label-free
quantification, as isotope-based quantification in these cases would require the laborious and
difficult production of labeled reference peptides for each protein to be measured (Pratt et al.,
2006).
While we attempted a number of different variations of quantification by peptide intensity,
including iBAQ, we found that straightforward quantification by proteins’ three most intense
peptides (TOP3), gave similar, consistent results (Silva et al., 2006; Schwanhausser et al., 2011).
Due to the difficulties of detecting multiple peptides from smaller molecular weight proteins, it is
also important to note that results from this analysis are most reliable for larger proteins.
We first applied this quantification method to triplicate isolations and MS analyses of mCherry
transcripts with or without an Act1 intron, purified with a first step isolation of Cbp80-PrA (Figure
4.5). Not surprisingly, MS2CP-GFP and Pab1p were dominant proteins, with about 5-fold higher
intensities than any others. This reflects MS2CP-GFP’s ability to bind to four MS2 hairpins as a
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Figure 4.5. Label free quantification of sequential Cbp80-PrA and MS2CP-GFP purifications of
mCherry with or without an Act1 intron. MS was performed on triplicate isolations of mCherry4xMS2 or mCherry(Act1 intron)-4xMS2.

Proteins were quantified by their top 3 peptide

intensities, and normalized to MS2CP-GFP. After filtering out known contaminants, the top 47
protein hits were grouped according to function (U1, U2, or catalytic snRNPs, members of the
Prp19 complex, or other RNPs) and visualized. While similar levels of non-splicing RNPs or U1
splicing factors were detected in both samples, other splicing proteins are strongly enriched with
the intron-containing transcript.
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dimer, giving it a predicted stoichiometry of 8 per transcript, and Pab1p’s tendency to bind the
polyA tail in multiple copies (Sachs et al., 1987). These and other non-splicing related RNPs were
found at roughly similar amounts in both intron and non-intron samples. Looking at splicing
factors, we also detected similar quantities of U1 snRNPs with both transcripts. However, later
spliceosomal factors, such as U2 and catalytic snRNPS or Prp19 complex components, were highly
enriched with the ACT1 intron-containing transcript. While most of these factors were not
identified in the intronless sample, those that were appeared at 10-100 fold lower levels.
To allow visualization of the relative levels of all identified proteins in two isolations, we also
graphed these data in a variation of a volcano plot (Figure 4.6). In this representation, each protein
is shown as a point, with the y-axis value indicating its maximum abundance in either sample, and
the x-axis value equal to the log value of its enrichment in one condition versus the other. Looking
at this plot to compare the presence and absence of the ACT1 intron, it is clear that all U1 snRNPs
are detected at approximately the same modest enrichment in the intron sample. A stronger
consistent enrichment is also seen for elements of the Prp19 complex, where it can also be noted
that Prp19p, which forms a tetrameric core of this complex, is roughly 4-fold more abundant than
other members of the complex. Finally, general mRNA-binding proteins like Pab1 and Cbp80 are
found along the y-axis, reflecting the expected equivalent abundances between the introncontaining and intronless transcripts.
Promoter-driven changes in transcript maturation
Several recent studies have revealed that promoter regions can independently confer downstream,
transcript-level regulatory alterations in their gene products (Bregman et al., 2011; Trcek et al.,
2011). As representative examples, we pursued classes of promoters responsive to glucose
starvation that confer different translational activity to their transcripts (Zid and O'Shea, 2014).
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Figure 4.6. Volcano plot of quantifications from sequential Cbp80-PrA and MS2CP-GFP
purifications of mCherry with or without an Act1 intron. Proteins quantified as in Figure 4.5 were
plotted according to the log 2 ratio of relative abundance in the mCherry(Act1 intron) sample over
the mCherry sample (x-axis). Y-axis values reflect protein abundance in the enriched sample,
relative to MS2CP-GFP. Proteins from the same complex, like U1 snRNPs, tend to be enriched
at similar levels. Proteins found in only one sample are shown at the corresponding edge of the
plot.
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While many genes are up-regulated at the mRNA level in response to glucose stress, only some,
such as HSP26, have concomitant increases in protein expression, while others, like GLC3,
surprisingly show no protein increase at all. The transcripts of these genes have been found to
localize to P bodies and stress granules, and are not actively translated during starvation. The
differential regulation of these two types of transcripts was found to be due solely to the
corresponding promoter sequence, and was independent of the transcript sequence. We thus
sought to identify possible RNP determinants of this regulation by expressing MS2-tagged
mCherry with either GLC3 or HSP26 promoters, and performing mRNA isolations under glucose
starvation conditions.
As promoter-driven changes in transcript composition would be predicted to occur cotranscriptionally, we isolated mRNA using Thp2-PrA as the tagged mRNP. Thp2p is a member
of the THO/TREX complex, recruited during transcription and involved in transcriptional
elongation (Jimeno et al., 2002; Strasser et al., 2002). One notable difference in RNP composition
was found in mCherry transcripts driven by the HSP26 promoter, rather than GLC3 or the TDH3
control (Figure 4.7 and 4.8). While members of the Prp19 complex are found at significant levels
with GLC3 or TDH3, these were not identified with the HSP26 sample. While the Prp19 complex
is predominantly recognized as an activator of splicing, it has more recently been shown to recruit
the TREX complex to at least some actively transcribed genes (Chanarat et al., 2011). The Prp19
complex appears to associate with RNA polymerase II, and is required for full association of the
THO/TREX complex to active genes, even those without introns. It has not been clear whether
the Prp19 complex is in fact required for efficient transcription at all genes, and our results suggest
that there may be cases, such as HSP26, where it is not necessary for THO/TREX recruitment.
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Figure 4.7. Label free quantification of sequential Thp2-PrA and MS2CP-GFP purifications of
mCherry expressed from HSP26 or GLC3 promoters. MS was performed on duplicate isolations
of HSP26-mCherry-4xMS2 or GLC3-mCherry-4xMS2 from yeast starved of glucose for 30
minutes. Proteins were quantified by their top 3 peptide intensities, and normalized to MS2CPGFP. After filtering out known contaminants, the top 34 protein hits were grouped according to
function (U1, U2, or catalytic snRNPs, members of the Prp19 or THO/TREX complexes, or other
RNPs) and visualized. While similar levels of THO/TREX and other non-splicing RNPs were
found in each sample, significantly more splicing proteins, particularly factors associating after
U1, were detected with the GLC3 promoter-driven transcript.
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Figure 4.8. Volcano plot of quantifications from sequential Thp2-PrA and MS2CP-GFP
purifications of mCherry expressed from an HSP26 or GLC3 promoter. Proteins quantified as in
Figure 4.7 were plotted according to the log 2 ratio of relative abundance in the GLC3 promoter
sample over the HSP26 promoter sample (x-axis). Y-axis values reflect protein abundance in the
enriched sample, relative to MS2CP-GFP. Later splicing factors like U2 or Prp19 complex
components are uniquely identified with the GLC3 promoter sample, while general factors like
Pab1p or THO/TREX factors are equally abundant in both experiments. Proteins found in only
one sample are shown at the corresponding edge of the plot.
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While we do isolate THO/TREX in these pullouts (a TREX component is in fact used to isolate
the associated transcript), it remains possible that the lack of Prp19 components found with the
HSP26 sample reflect different kinetics of this recruitment.
While more evidence is needed before we can suggest any link between the Prp19 complex and
the different fates associated with HSP26 and GLC3 transcripts once exported from the nucleus,
it is an intriguing possibility. We can thus perform additional controls to determine whether this
complex is indeed required for promoter-dependent regulation of these transcripts. First, we can
repeat Thp2-based mRNP isolations of all transcripts with and without glucose starvation. If Prp19
is playing a role in transcriptional response to this stress, it should be detected at different levels
when cells are starved. We can also tag a Prp19 factor rather than Thp2 for RNA purifications –
this could aid detection of other proteins involved in transcript-specific regulation that interact
with the Prp19 complex. Further, to confirm that the conditions used are in fact leading to changes
in cytoplasmic processing, we will repeat these purifications using a cytoplasmic mRNP, such as
Cdc33p. This would be expected to isolate P body or stress granule components in the case of
activated GLC3, but not HSP26.
It is also possible that Prp19 is intrinsically required for full transcription from some promoters
and not others, independent of activation of the stress-response genes we investigated. To pursue
this, we can investigate the Thp2-bound mRNP composition of a broader range of transcripts,
including those with either constitutive or inducible promoters.

This could demonstrate

differential involvement of Prp19, and potentially reveal other factors able to take the place of
Prp19 in THO/TREX recruitment.
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Ribosomal protein introns
A number of studies have suggested differences in the ways that certain introns are processed.
This has been clearest in the case of a number of ribosomal protein genes that appear to be
differentially degraded and spliced. For instance, pre-mRNAs of a number of such genes, but not
intron-containing genes generally, were found to be targeted for degradation by the nuclear
exosome in a Nab2p-dependent manner (Schmid et al., 2012). Moreover, it has been seen that
different classes of spliced genes have distinct mechanisms of splicing, as observed by differences
in splicing efficiency and sensitivity to various spliceosome mutants (Pleiss et al., 2007).
Ribosomal protein genes are notable for their atypically high relative levels of spliced versus
unspliced precursor RNA, as well as for their distinct susceptibilities to different spliceosomal
defects.
To investigate these questions of intron-dependent processing, we compared mCherry transcripts
containing an intron from either ACT1 or RPS30b, a representative ribosomal protein gene, as
well as an intronless control. The lengths of these introns (309 bp and 411 bp, respectively) are
similar, and thus not expected to contribute to significant differences in splicing activity. We MS2tagged and isolated these transcripts for MS analysis, using Cbp80-PrA as the RNP purification
target to maximize yield of spliceosome-associated RNA. Quantitative comparison of associated
RNP factors revealed striking differences between these samples (Figure 4.9 and 4.10). First, U1
and U2 snRNPs, the earliest to bind an intron as part of the prespliceosome complex (complex A),
are enriched about 3-fold in the ACT1 vs RPS30b intron. Conversely, elements of the activated
and catalytic spliceosome (complex B act or C) are enriched 3-fold in the RPS30b intron. This
includes the Prp19 complex, all members of which are enriched to similar extents with the RP30b
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Figure 4.9. Label free quantification of sequential Cbp80-PrA and MS2CP-GFP purifications of
4xMS2-tagged mCherry containing an intron from either Act1 or Rps30b. MS was performed
after mRNP isolations performed in triplicate. Proteins were quantified by their top 3 peptide
intensities, and normalized to MS2CP-GFP. After filtering out known contaminants, the top 47
protein hits were grouped according to function (U1, U2, or catalytic snRNPs, members of the
Prp19 complex, or other RNPs) and visualized. Similar levels of non-splicing RNPs are seen in
each sample, but while the Act1 intron co-purifies higher levels of U1 and U2 components, factors
from later spliceosome subunits are strongly enriched with the Rps30b intron sample.
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Figure 4.10. Volcano plot of quantifications from sequential Cbp80-PrA and MS2CP-GFP
purifications of mCherry with an intron from either Act1 or Rps30b. Proteins quantified as in
Figure 4.9 were plotted according to the log 2 ratio of relative abundance in the Rps30b intron
sample over the Act1 intron sample (x-axis). Y-axis values reflect protein abundance in the
enriched sample, relative to MS2CP-GFP. While earlier U1 and U2 splicing subunits are enriched
with the Act1 intron, later catalytic subunits are more abundant in the Rps30b intron sample. In
all cases, proteins associated with a particular splicing complexe are found at a similar relative
enrichment. Proteins found in only one sample are shown at the corresponding edge of the plot.
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intron. Notably, two U2-associated proteins, Lea1p and Msl1p, are present at equivalent amounts
in both samples; these proteins directly associate in a complex with U2 snRNA, and may therefore
persist with the core U2 snRNP through the splicing process, in contrast to the other U2 proteins
detected.
The differential enrichments of these complexes could be explained by several factors. Most
obviously, different kinetics of the splicing process for each intron could lead to varying
enrichment of transcripts in earlier versus later steps of splicing. Thus if the ACT1 intron remains
associated longer with the prespliceosome before catalytic splicing occurs, we could expect the
observed increase in prespliceosomal U1 and U2 snRNPs over catalytic proteins (Figure 4.11).
There is in fact reason to believe this is the case – a number of ribosomal protein genes have been
seen to have proportionally less unspliced pre-mRNA than ACT1 (Pleiss et al., 2007). While the
reason for this has not been clear, our results would suggest that the ACT1 intron is delayed at the
presplicesome step, before components of the precatalytic splicesosome (complex B) associate.
Related evidence is also consistent with, and may help explain, our results. Relative to the RPS30b
gene, ACT1 shows a significantly different response to a number of spliceosome mutations. Most
dramatically, in response to a temperature-sensitive PRP19 mutation, the level of spliced, mature
ACT1 mRNA is dramatically reduced (with no change in pre-mRNA level), while RPS30b shows
only a strong increase in pre-mRNA (Pleiss et al., 2007). This suggests a difference in the limiting
steps of splicing for each of these introns. While a defect in Prp19p (but not other splicing factors,
interestingly) impairs the removal of the ACT1 intron, the pool of pre-mRNA is not affected. This
may be consistent with a predominance of pre-spliceosome-associated ACT1 mRNA, with a
highly active Prp19 complex required for efficient processing of the small subset of mRNA
proceeding to splicing. In contrast, the RPS30b intron, which is predominantly associated with
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Figure 4.11. Hypothetical model of kinetic differences in splicing of the Act1 and Rps30b introns.
Due to its relative enrichment of U1 and U2 snRNPs, the Act1 intron appears to be rate-limited in
its transition to the precatalytic form of the spliceosome (Complex B). The Rps30b intron is
instead more strongly associated with components of this complex. More efficient procession to
Complex B could result from this intron’s specific recruitment of Npl3, known to promote
recruitment of certain splicing factors.
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the catalytic spliceosome, continues to be processed even with a defective Prp19 complex,
presumably due to the large pool of mRNA consistently associated with this complex. More
thorough investigation of the dynamics of splicing for these and other introns will be necessary to
conclusively determine the factors differentiating their processing.
Additional differences of note were observed between the ACT1 and RPS30b introns.
Interestingly, only the RPS30b intron was found to co-isolate with Npl3p. This SR protein is
primarily known for its role in mRNA export, but has also been shown to promote splicing for a
subset of intron-containing genes by aiding recruitment of other splicing factors (Kress et al.,
2008). Consistent with our results, efficient splicing of RPS30b, but not ACT1, was found to
depend on Npl3p activity. As Npl3p was only detected in the presence of the RPS30b intron, its
enhancement of splicing activity appears to depend on intron-specific association. Conceivably,
the inability of the ACT1 intron to recruit Npl3p may be associated with its distinctive pattern of
early spliceosome association (Figure 4.11).

Finally, as expected, Nab2p was found at

significantly higher levels in the RPS30b intron sample. This is consistent with studies showing
that pre-mRNA of RPS30b and other ribosome protein genes is specifically regulated by the
exosome in a Nab2p-dependent manner (Schmid et al., 2012).
The differences in splicing factor occupancy we found in our initial isolations of Cbp80passociated ACT1 or RPS30b introns suggest a number of avenues for future investigation. First,
as Npl3p appears to be a key mRNP factor with a role in splicing specific to the RPS30b intron,
this is a promising protein to target in future sequential purifications of intron-containing
transcripts. Such mRNA isolations could provide additional evidence relating to the mechanism
of Npl3p’s apparent activation of splicing. As Npl3p has a number of different roles in multiple
steps of mRNA processing, this RNA-specific approach is uniquely able to differentiate
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interactions specific to RPS30b intron processing from those involved in generic mRNA
maturation. In addition, given the broad differences we observed in introns’ enrichment of early
versus late splicing factors, a more comprehensive and detailed view of the divergent splicingrelated factors could be obtained through sequential isolations using representative spliceosome
proteins.

Snu71p and Snu114p, for instance, would enrich either the U1-dominated

prespliceosome or the catalytic spliceosome, respectively. This more precise targeting would
allow us to isolate specific stages of splicing, giving a finer picture of where intron-specific protein
factors act during the splicing process. This should indicate, for instance, whether the difference
we observe in ACT1’s relative enrichment of early splicing factors is only a kinetic phenomenon
– in this case a purification with Snu114p should purify the same catalytic spliceosome as one
obtained with the RPS30b intron. Differential isolation of intron-specific proteins like Npl3p in
these experiments could also suggest where these factors might act to generate differences in
splicing activity.
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Chapter 5: Discussion
Development and applications of new nanobodies
The novel mass spectrometry and DNA sequencing-based approach to nanobody discovery that
we developed has a range of long-term applications. Our method is well-suited to the development
of nanobody reagents against various types of protein targets, including proteins that are difficult
to tag. The versatility and potential of nanobodies is huge, as reflected by the interest of the
research community (Huang et al., 2010; Romer et al., 2011; Vanlandschoot et al., 2011;
Muyldermans, 2013). Nanobodies have great potential in drug development, as they are much
smaller than antibodies, resistant to aggregation, and can be readily humanized (Revets et al., 2005;
Vincke et al., 2009; Muyldermans, 2013); they can bind with great specificity and efficacy to
disease targets such as tumor cells, either independently (as a monomer or an ultra-high affinity
nanobody dimer), or as a fusion with other protein domains, molecules, or drugs (Els Conrath et
al., 2001; Jahnichen et al., 2010; Roovers et al., 2011; Ulrichts et al., 2011). As demonstrated here,
the ability of our method to quickly and easily identify large repertoires of high affinity bacteriallyexpressed nanobodies against a chosen target antigen has the potential to significantly advance a
field that otherwise can take months or years to generate such reagents (Muyldermans, 2013).
Nanobodies have a number of unique properties that make them well-suited for certain other
applications. In microscopy, their small size allows for improved permeability into cell and tissue
samples, improving performance, for instance, in super-resolution studies (Ries et al., 2012).
These reagents have further potential to improve other techniques reliant on efficient fluorescent
labeling.

Volume imaging of tissue samples is a particularly demanding technique, as

immunolabeling and clearing of these large structures can take weeks with standard antibodies
(Renier et al., 2014). Fluorescently labeled nanobodies, being an order of magnitude smaller, are
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a promising alternative for these studies, and preliminary results have indeed indicated their
suitability for more effective large tissue labeling. An additional advantage of nanobodies’ small
size and monovalency is their ability to bind their target at an equimolar ratio. When covalently
conjugated with dye, this means that their fluorescent signal will increase linearly with the amount
of target protein. This allows for quantitative labeling of samples, as we have observed in
preliminary experiments (with the M. Tessier-Lavigne lab).

Finally, in all microscopy

applications, the ability of multiple nanobodies to simultaneously bind separate epitopes on their
antigen means that total signal intensity can be correspondingly increased. With our anti-GFP
nanobody repertoire, we have found that up to three nanobodies with distinct epitopes can be used
to label GFP samples without effect on each other’s binding, leading to three-fold higher signal.
More broadly, our pipeline for nanobody identification has allowed us to simultaneously immunize
llamas with many antigens at once, and successfully generate several repertoires concurrently.
While we have only begun taking advantage of this ability, we are already significantly increasing
the output of nanobodies against many new targets of interest. As a start, we have generated
several nanobodies against three proteins of recent biomedical interest: the cancer-associated
CTLA4 and EPHA2 receptors, and dystrophy-linked dysferlin protein. CTLA4 and EPHA2
nanobodies are being actively assessed for in vivo effects on their targets’ signaling pathways, and
dysferlin nanobodies are undergoing validation. Given the medical importance of these three
proteins, biologically active nanobodies can potentially be of immediate diagnostic or therapeutic
use. Moving beyond these three targets, with which we have found early success, we are actively
pursuing nanobodies against novel targets of interest. This includes BTLA and HVEM, two
receptors expressed by a variety of lymphocytes, normally involved in inhibiting T cell activation
when they interact with each other (Gavrieli et al., 2006). Similar to CTLA4 however, changes in

107

expression of these two receptors are common features of certain types of cancer, resulting in
suppression of the immune response to these tumors (Pasero and Olive, 2013). Antibodies to these
two proteins blocking their interactions could thus be valuable therapeutic tools, and we are
currently working to generate nanobodies for this purpose.
Alongside our efforts on immediately relevant biomedical targets, we are also developing
nanobodies against a number of other biologically significant proteins. Given our lab’s interest in
the structure and function of the nuclear pore complex, we have begun generating nanobodies
against a variety of nucleoporins. This has started with immunizations of 11 different mammalian
proteins, with a particular focus on those factors implicated in cancer biology (Simon and Rout,
2014). Lastly, we are aiming to develop nanobody reagents against several mammalian RNA
processing factors, as well as key retrotransposition factors (Taylor et al., 2013).
In sum, the ability to rapidly generate sets of nanobodies has allowed us to produce reagents
enabling diverse avenues of research. We can generate nanobodies against more than ten antigens
in parallel with limited labor, making this an efficient and widely available pipeline. The
nanobodies identified can be readily produced in unlimited quantities, and are immediately useful
for affinity capture or related techniques. Moreover, the recombinant proteins are easily modified
to allow for myriad other uses, from straightforward dye labeling for fluorescent imaging, to
protein engineering of customized nanobodies designed for specialized applications.
Tools for the study of single mRNP complexes
For our investigations into yeast mRNP processing pathways, high efficiency anti-GFP nanobodies
were one element enabling the development of a new approach to the isolation of RNA-specific
pools of RNP complexes. With the use of highly efficient isolations of affinity tags, we are able
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to perform robust purifications of MS2-tagged RNAs associated with any RNP factor of interest.
This has allowed us to begin investigating the composition of mRNP complexes associated with
the many different alternative processing pathways suspected to regulate mRNA transcripts. Until
now, only the highest abundance RNP factors have been successfully identified through isolations
of tagged RNAs (Said et al., 2009; Hogg and Goff, 2010; Tsai et al., 2011), in contrast to the many
specialized proteins we have identified in our two-step approach. Aside from greater overall
sensitivity, the use of a tagged RNP factor as a first purification target allows analysis of a specific
step or mechanism of mRNA processing.
We have started to take advantage of this novel RNP purification approach in a preliminary survey
of RNA sequence elements of interest. In addition to confirming the efficacy of our approach by
identifying known protein interactors of well-studied mRNA elements like the ASH1 transcript’s
3’ UTR, our survey has already begun to provide insight into potentially novel mRNP interactions.
For example, isolations of transcripts containing either ACT1 or RPS30b introns has revealed
significant differential enrichment in various subcomplexes of the spliceosome. While the ACT1
intron predominantly isolates early prespliceosome factors, the RPS30b intron shows significant
enrichment of catalytic spliceosomal proteins, along with specialized activators of splicing like
Npl3p (Kress et al., 2008).
While previous studies in yeast have provided strong evidence that certain introns, particularly
those of ribosomal protein genes, require different factors for efficient splicing, or are spliced at
different rates, these conclusions have largely relied on indirect observations (Pleiss et al., 2007;
Kress et al., 2008; Schmid et al., 2012). This has typically involved observing changes in the
relative amounts of spliced and unspliced transcript in various mutant strains. While instructive,
this experimental approach provides only indirect genetic insight into the mechanisms behind these
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intron-specific differences. Through proteomic analysis of isolated intron-containing transcripts,
we have now directly identified changes in the composition of mRNP components specific to
different types of introns. While still preliminary, this data has been consistent with the previous
genetic work on these introns, and has provided insight into potential mechanisms involved in
transcript-specific differences in splicing.
Potential applications of sequential RNP purifications
Beyond the set of mCherry derivatives that we used for our preliminary survey of mRNA sequence
elements, there are countless other questions of RNA biology that could be studied with variations
of our sequential purification methodology. An obvious next step is to tag and isolate wholly
endogenous transcripts. Given a moderate level of transcriptional activity, our approach is likely
to allow equally efficient purifications of any transcript – there is nothing in our system uniquely
tailored to the mCherry sequence so far used. There are many questions that could be addressed
by isolations of such RNAs. As it is unclear how a coding sequence itself does or does not affect
mRNP composition, this could be examined by comparing the RNPs co-purified with different
types of mRNA sequence. Transcripts of different lengths, for instance, could be examined to
identify factors whose stoichiometry are or are not dependent on transcript size. Evidence from
genome-wide studies suggests that different RNPs may in fact have different length-dependence
(Baejen et al., 2014). Alternatively, transcripts expressed at different levels could be similarly
investigated, with a potential focus on codon adaption index, which is closely associated with a
gene’s protein expression level (Sharp and Li, 1987; Jansen et al., 2003). Beyond these questions
of RNPs preferentially associated with certain broad transcript characteristics, any specific mRNA
believed to have unique RNP components of interest can be easily tagged and purified with our
sequential method. More and more such transcripts continue to be identified by various groups,
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and there remain many such outstanding candidates: heat shock proteins with unique RNA-level
regulation, or transcripts regulated during the cell cycle are two examples of many (Saavedra et
al., 1997; Trcek et al., 2011).
Importantly, our system of RNA isolation is not specific to mRNA at all. As long as an MS2
hairpin tag can be inserted into a sequence of interest without undue effect on RNA structure, a
fundamentally identical approach can be taken with any class of RNA, such as rRNAs or noncoding RNAs (ncRNAs). ncRNAs in particular have been of increasing interest to the scientific
community, and comparatively little is known about processing specific to such sequences,
particularly long ncRNAs (lncRNAs) (Mattick and Makunin, 2006; Gupta et al., 2010; Tuck and
Tollervey, 2013). While often degraded in the nucleus by surveillance machinery, studies have
suggested that certain ncRNA sequences are exported to the cytoplasm (Xu et al., 2009). Hrp1p
and Nab2p have been implicated in these different outcomes through preliminary genome-wide
studies (Tuck and Tollervey, 2013), and are thus prime candidates for targets in RNP-specific RNA
isolations. Cytoplasmic factors can similarly be used to identify possible roles for these transcripts
after export.
Finally, while our work in MS2-based RNA isolations has so far been limited to yeast, there is
nothing preventing these techniques from being directly applied to other systems, such as
mammalian cells. The MS2/MS2CP system itself has been extensively used in mammalian cell
culture (Rodriguez et al., 2007; Querido and Chartrand, 2008), and our lab has optimized our
protein tagging and affinity isolation approach to achieve results comparable to those in yeast in a
multitude of model organisms, including mammalian tissue culture and even tissue (Domanski et
al., 2012; Shi et al., 2015; Obado et al., 2016). As the sequential RNA purification method
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fundamentally relies only on the combination of these two technologies, there is little reason to
believe it cannot be easily adapted to any common laboratory model system.
Conclusions
The work presented here has aimed to provide a methodological framework first and foremost for
the isolation of RNA-specific mRNPs. This involved identifying highly effective reagents for
affinity isolation of protein tags, primarily PrA and GFP. In the process of generating such
reagents in the form of high affinity nanobodies, we have also developed a pipeline for rapid
identification of nanobody repertoires against any antigen of interest. This has allowed us to
efficiently pursue sets of novel affinity reagents against a variety of targets of biomedical interest.
With improved nanobodies available, we have been able to develop a specific and efficient
sequential affinity technique for isolating a single species of mRNA transcript associated with a
given RNP factor. After confirming and optimizing the effectiveness of this approach, we began
applying it to a small number of transcript sequence elements suspected to undergo unusual mRNA
processing. While this survey is still in progress, initial results have revealed a number of
transcript-specific changes in mRNP composition. Specifically, we have isolated confirmed
factors associated with the well-studied Ash1 3’UTR, and identified potential new interacting
factors. We have also found differences in patterns of spliceosome association with different
introns, offering potential mechanistic insight into differences in splicing activity previously
associated with these introns. Moreover, early experiments have suggested possible RNP factors
responsible for mediating promoter regions’ determination of their transcripts’ downstream
cellular fate. While more work remains to confirm and explore our preliminary results relating to
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the biology of the mRNA transcripts we surveyed, the methods we have developed are already
allowing routine investigation of RNA-specific RNP complexes. This will enable expansion of
our survey to additional mRNAs or ncRNAs of biological interest.
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Chapter 6: Materials and Methods
Nanobody generation and characterization
Isolation of V H H antibodies
A 5 year old female llama, Barbie, was immunized with recombinant GFP-His 6 , and a 4 year old
male llama, Marley, with recombinant mCherry-His 6 through subcutaneous injections of 5 mg of
protein with CFA. Three additional injections of 5 mg protein, with IFA, were performed at three
week intervals. Serum bleeds were obtained 10 days after the final injection. 2.5 ml of serum was
diluted ten-fold in 20 mM sodium phosphate, pH 7.0, and incubated with Protein G-agarose resin
for 30 min. The flow-through was then incubated for 30 min with Protein A-agarose resin. Both
resins were washed with 20 mM sodium phosphate, pH 7.0, and bound VHH IgG was eluted with
100 mM acetic acid, pH 4.0 and 500 mM NaCl (Protein G resin) or 100 mM acetic acid, pH 3.5
and 150 mM NaCl (Protein A resin). These elutions were pooled and dialyzed into PBS. 3 mg of
this VHH fraction was then incubated with Sepharose-conjugated GFP. This resin was washed
with 10 mM sodium phosphate, pH 7.4 and 500 mM NaCl, followed by 1-4.5 M MgCl 2 in 20 mM
Tris, pH 7.5, and then equilibrated in PBS. The resin was then digested with 0.3 mg/ml papain in
PBS plus 10 mM cysteine, for 4 hours at 37°C. The resin was then washed with 1) 10 mM sodium
phosphate, pH 7.4 and 500 mM NaCl 2) PBS plus 0.1% Tween-20 3) PBS 4) 0.1 M NH 4 OAc, 0.1
mM MgCl 2 , 0.02% Tween-20. Bound protein was then eluted for 20 min with 0.1 M NH 4 OH and
0.5mM EDTA, pH 8.0. These elutions were dried down in a SpeedVac and resuspended in LDS
plus 25 mM DTT. The samples were alkylated with iodoacetamide and run on a 4-12% Bis-Tris
gel. The ~15 kDa band corresponding to the digested VHH region was then cut out and prepared
for MS.
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RT-PCR and DNA sequencing
Bone marrow aspirates were obtained from immunized llamas concurrent with serum bleeds.
Bone marrow plasma cells were isolated on a Ficoll gradient using Ficoll-Paque (GE Healthcare).
RNA was isolated from approximately 1-6 x 107 cells using Trizol LS reagent (Thermo Fisher),
according to the manufacturer’s instructions. cDNA was reverse-transcribed using Ambion
RETROscript (Thermo Fisher). A nested PCR was then performed with IgG specific primers. In
the first step, CALL001 (5’-GTCCTGGCTGCTCTTCTACAAGG-3’) and CALL002 (5’GGTACGTGCTGTTGA ACTGTTCC-3’) primers were used to amplify the IgG variable domain
into the CH2 domain (Conrath et al., 2001). The approximately 600-750 bp band from VHH
variants lacking a CH1 domain was purified on an agarose gel. Next, for 454 sequencing, VHH
regions were specifically reamplified using framework 1- and 4-specific primers with 5’ 454
adaptor

sequences:

454-VHH-forward

(5’-CGTATCGCCTCCCTCGCGCCATCAG

ATGGCT[C/G]A[G/T]GTGCAGCTGGTGGAGTCTGG-3’)
(5’-CTATGCGCCTTGCCAGCCCGCTCAG

and

454-VHH-reverse

GGAGACGGTGACCTGGGT-3’)

(adaptor

sequences are underlined) (Conrath et al., 2001). The approximately 400 bp product of this
reaction was gel purified, then sequenced on a 454 GS FLX system after emPCR amplification,
on one Pico Titer Plate. For Illumina MiSeq sequencing, the second PCR was instead performed
with random 12-mers replacing adaptor sequences, to aid in cluster identification: MiSeq-VHHforward (5’-NNNNNNNNNNNN ATGGCT[C/G]A[G/T]GTGCAGCTGGTGGAGTCTGG-3’)
and MiSeq-VHH-reverse (5’-NNNNNNNNNNNN GGAGACGGTGACCTGGGT-3’).

The

product of this PCR was gel purified, ligated to MiSeq adaptors before library preparation using
Illumina kits, and run on a MiSeq sequencer with 2 x 300 bp paired end reads.

115

Database preparation
The protein sequence databases used for identification were prepared by translating sequencing
reads in all 6 reading frames, and for each read the longest Open Reading Frame (ORF) was
selected. The selected ORF was digested with trypsin in silico and a list of unique tryptic peptides
of 7 amino acids or longer was constructed and saved in a FASTA file. It is important to construct
a FASTA file only containing unique peptides because even though most search engines can
handle some sequence redundancy, they are not well equipped to handle the extreme redundancy
that is provided by next generation sequencing of the single chain antibody locus and search
engines either become very slow or crash if presented with such an extreme redundancy.
Mass spectrometry
Gel sections containing V H H domains were excised, destained, and dehydrated. MS analysis was
performed by Yinyin Li as follows. The dehydrated gel slices were subjected to in-gel digestion
with proteomic-grade trypsin (80 µL; 25 ng trypsin, 25 mM ammonium bicarbonate) (Promega)
at 37 °C overnight. The gel was extracted once with extraction solution (140 µL; 67% acetonitrile,
1.7 % formic acid). The resulting proteolytic digest was cleaned with a STAGE tip(Rappsilber et
al., 2003) and loaded onto a home-packed reverse phase C18 column (75 µm I.D., 15 µm tip) (New
Objective) with a pressurized bomb. The loaded peptides were subsequently separated with a linear
gradient (0 % to 42 % acetonitrile, 0.5 % acetic acid, 120 min, 150 nL/min after flow splitting)
generated by an Agilent 1260 HPLC and directly sprayed into an LTQ-Velos-Orbitrap mass
spectrometer (Thermo Scientific) for analysis. In the mass spectrometer, a survey scan was carried
out in the orbitrap (resolution = 30,000, AGC target = 1E6) followed by tandem MS in the ion trap
(AGC target = 5E3) of the top twenty most intense peaks. Tandem MS was carried out with
collision induced dissociation (isolation width = 2 Th, CE = 35 %, activation time = 5 ms). Internal
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calibration was used for improved mass accuracy (lock mass m/z = 371.1012). In order to scan
more peptides, both predictive AGC and dynamic exclusion were enabled (Repeat counts: 2, repeat
duration: 12 s, exclusion duration: 60 s). Single and unassigned charge species were excluded from
tandem MS scans. The raw files were converted into mzXML format with ReAdW (version 4.3.1).
MS-based identification of VHH sequences
Searching and ranking of candidate sequences was carried out by Yinyin Li and Sarah Keegan.
The MS search was performed on the custom database of tryptic peptides using the X! Tandem
search engine. Then, the identified peptides filtered by expectation value were mapped to the
sequences translated from 454 reads (longest ORF only, as described above). The CDR regions
were located within the sequence based on approximate position in the sequence and the presence
of specific leading and trailing amino acids. For example, to locate the CDR3 region, the algorithm
searched for the left anchor YXC (X representing any amino acid) between position 93 and 103 of
the sequence, and the right anchor WG between position n-14 and n-4 of the sequence, where n is
the length of the sequence. Once the peptides were mapped to the sequences and their CDR
regions, a metric was calculated to rank each sequence as a potential candidate based on the
bioinformatics evidence available. The factors included in the metric were: MS coverage and
length of individual CDR regions with CDR3 carrying highest weight, overall coverage including
framework region, and a count of the 454 reads producing the sequence. Finally, sequences with
similar CDR3 regions were grouped together, allowing for the identification of the highest
confidence sequence corresponding to a particular CDR3. A sequence was assigned to a group
where its hamming distance to an existing member was 1, i.e. there was one amino acid difference
in the sequence, and different groups that have one shared sequence were further combined. By
choosing sequence hits from different groups for production, we maximized the overall sequence
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diversity of the candidate pool. The candidate list was displayed for manual inspection as an
interactive HTML page with CDR regions annotated, peptide mapping information and the ranking
metrics shown for each sequence. All algorithms described above were implemented in Perl.
Web-based application for nanobody sequence identification: “Llama-Magic”
The pipeline that was used for identification of the Nanobody sequences has been automated and
can be accessed through a web-based interface at http://www.llamamagic.org. Llama-Magic
allows upload of FASTA files containing reads from High-throughput DNA sequencing. Once
uploaded, the reads will be automatically translated and digested to create an MS searchable
database of tryptic peptides, as described above. Next, the MS (mgf) files can be uploaded for a
selected tryptic peptide sequence database, and the parent and fragment error can be chosen for
the X! Tandem search. Once the mgf files are uploaded, the X! Tandem search will be executed
and the matching peptides saved. Then (1) annotation of CDR regions, (2) mapping of the
identified peptides and (3) ranking and grouping of candidates are performed automatically,
producing an interactive display of the candidate list showing detailed information regarding each
sequence and its corresponding rank. Llama-Magic is implemented in Perl, HTML and JavaScript.
Manual inspection was performed to make sure a) long CDR3 peptides, which embrace both
variable regions and framework regions, have fragmentation pattern within the variable regions;
b) CDR3 peptides are unique enough (uniqueness score < 100);
Cloning
Nanobody sequences were codon-optimized for expression in E. coli and cloned into pCR2.1 after
gene synthesis (Eurofins MWG Operon), incorporating BamHI and XhoI restriction sites at 5’ and
3’ ends, respectively. A pelB leader sequence was cloned into pET21b at NdeI and BamHI
restriction sites using complementary primers: 5’-tatgaaatacttattgcctacggcagccgctggattgttattact
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cgcggcccagccggccatggctg-3’ and 5’-gatccagccatggccggctgggccgcgagtaataacaatccagcggctgccgtag
gcaataagtatttca-3'. Nanobody sequences were then subcloned into pET21b-pelB using BamHI and
XhoI restriction sites, with primers also encoding a PreScission Protease cleavage site just before
the C-terminal 6xHis tag.
Purification of nanobodies
pelB-fused nanobodies were expressed under a T7 promoter in Arctic Express (DE3) cells
(Agilent), induced with IPTG at a final concentration of 0.1 mM. Cells were induced for 18-20
hours at 12°C, then pelleted by a 10 min spin at 5000 x g. The periplasmic fraction was then
isolated by osmotic shock(Skerra and Pluckthun, 1988). This fraction was bound to His-Select
nickel affinity resin (Sigma), washed with His wash buffer (20 mM sodium phosphate pH 8.0, 1
M NaCl, 20 mM imidazole), and eluted with His elution buffer (20 mM sodium phosphate pH 8.0,
0.5 M NaCl, 0.3 M imidazole). The elution was then dialyzed into PBS.
Fluorescent protein binding assays
2 µg of fluorescent protein was added to 50 µl of 2 mg/ml E. coli lysate diluted in binding buffer
(20mM HEPES, pH 7.4, 350 mM NaCl, 0.01% Tween-20, 0.1 M PMSF, 3 µg/ml pepstatin A).
This was incubated with 25 µl of nanobody-Dynabead slurry. After a 30 minute incubation at 4°C,
beads were washed with binding buffer and bound protein was eluted with 15 µl LDS. Elutions
were run on a 4-12% Bis-Tris gel.
K d determinations
SPR measurements were obtained on a Proteon XPR36 Protein Interaction Array System (BioRad). Recombinant 1xproA, 2xproA, and 4xproA was immobilized on a ProteOn GLC sensor
chip: the chip surface was first activated with 50 mM sulfo-NHS and 50 mM EDC, run at a flow-
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rate of 30 µl/min for 300 sec. The ligand was then diluted to 2-6 µg/ml in 10 mM sodium acetate,
pH 5.0, and injected at 25 µl/min for 75 sec. Finally, the surface was deactivated by running 1 M
ethanolamine-HCl (pH 8.5) at 30 µl/min for 300 sec. This led to immobilization of approximately
200-600 response units (RU) of ligand.
K d s of recombinant nanobodies were determined by injecting 4 or 5 concentrations of each protein,
in triplicate, with a running buffer of 20 mM HEPES, pH 8.0 / 150 mM NaCl / 0.01% Tween.
Proteins were injected at 50 µl/min for 120 sec, or 100 µl/min for 90 sec, followed by a dissociation
time of 600 sec. Between injections, residual bound protein was eliminated by regeneration with
4.5 M MgCl 2 in 10 mM Tris, pH 7.5, run at 100 µl/min for 36 sec. Binding sensorgrams from
these injections were processed and analyzed using the ProteOn Manager software. Binding curves
were fit to the data with a Langmuir model, using grouped k a , k d , and R max values.
Immunofluorescence microscopy
HeLa cells were cultured on coverslips in DMEM media with 10% FBS and
penicillin/streptomycin at 37°C with 8% CO 2 in a humidified environment. Cells tested negative
for mycoplasma. Cells were transfected with CellLight Tubulin-GFP or Mitochondria-GFP
BacMam 2.0 reagents (Thermo Fisher) using 4 µL of reagent per 5,000 cells, and processed after
18-20 hrs. Cells were fixed in ice-cold methanol for 10 minutes (for Tubulin-GFP) or in 2%
paraformaldehyde for 10 minutes (for Mitochondria-GFP). Cells were permeabilized with 0.5%
Triton for 10 min. and blocked for 1 hr with 10% goat serum / 1% BSA in PBS. They were then
incubated for 1 hr at room temperature with recombinant nanobody conjugated to Alexa Fluor®
568 succinimidyl ester (Thermo Fisher), diluted to 100 ng/ml in 1% BSA in PBS. Cells were
washed four times with PBS / 0.01% BSA, with 300 nM DAPI included in the final wash, then
mounted with ProLong Diamond (Thermo Fisher).
120

Wild-type and Sec13-GFP tagged T. brucei strains were cultured to a cell density of 1x107 as
previously described (DeGrasse et al., 2009). Cells from each strain were mixed 1:1, and fixed for
10 minutes with cold 4% formaldehyde. Approximately 1x106 cells were spotted onto coverslips,
allowed to settle for 30 min., permeabilized with 0.1% Triton for 5 min., and blocked with 10%
goat serum / 1% BSA in PBS for 30 minutes. Cells were then stained, washed, and mounted
identically to HeLa cells.
A S. cerevisiae W303 strain with Htb2 genomically tagged at the C-terminus with mCherry was
grown to mid-log phase, and allowed to settle on Concanavalin A-coated coverslips. Yeast were
fixed in 4% paraformaldehyde / 2% sucrose / PBS, and blocked and permeabilized for 30 minutes
in 0.25% Triton / 2% milk / PBS(Ries et al., 2012). Cells were stained overnight at 4°C with
nanobody diluted to 3.3 µg/ml in 0.25% Triton / 1% BSA / PBS. They were then washed 5 times
with 0.01% BSA in PBS, the final two washes for 5 min. Cells were mounted in 70% glycerol /
PBS.
All images were obtained on a Deltavision Image Restoration Microscrope (Applied
Precision/Olympus), with an Olympus 100x/1.40 numerical aperture objective, or 60x/1.42
objective in the case of HeLa cells. Raw images were processed by a deconvolution algorithm
using softWorX software (Applied Precision/GE Healthcare).
Affinity isolations of tagged protein complexes
Recombinant nanobodies were conjugated to epoxy-activated magnetic Dynabeads (Thermo
Fisher), with minor modifications to published IgG coupling conditions (Alber et al., 2007). 10
µg recombinant protein was used per 1 mg of Dynabeads, with conjugations carried out in 0.1 M
sodium phosphate, pH 8.0 and 1 M ammonium sulfate, with an 18-20 hour incubation at 30°C.
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Affinity isolations of yeast Nup84-GFP were carried out as previously described, using binding
buffer consisting of 20 mM HEPES, pH 7.4, 500 mM NaCl, 2 mM MgCl 2 , 0.1% CHAPS, 0.1M
PMSF, and 3 µg/ml pepstatin A(Alber et al., 2007). For each experiment, 50 µl of bead slurry was
used with 0.5 g of yeast cells. Similar conditions were used for HTB2-mCherry isolations (from
yeast with HTB2 genomically tagged at the C-terminus with mCherry(Rout et al., 2000)), except
lysate was sonicated 4 times for 10 s before centrifugation, and the binding buffer consisted of 20
mM HEPES, pH 8.0, 300 mM NaCl, 110 mM KOAc, 0.1% Tween-20, 0.1% Triton X-100, 0.1M
PMSF, and 3 µg/ml pepstatin A. Isolations of RBM7-LAP from HeLa cells were performed as
previously described(Domanski et al., 2012). 10 µl of bead slurry was used with 100 mg of cells,
using a binding buffer of 20 mM HEPES, pH 7.4, 300 mM NaCl, 0.5% Triton X-100, with
cOmplete Protease Inhibitor, EDTA-free (Roche).
To determine affinity isolation yields, samples of resuspended lysate were taken before and after
Dynabead binding. These were run on a 4-12% Novex Bis-Tris gel in MES running buffer (Thermo
Fisher), and probed by Western blotting using mouse anti-GFP antibody (Roche, cat. no. 11 814
460 001) diluted 1:1,000 in TBST / 2% dry milk and an anti-mouse, HRP-conjugated secondary
(GE Healthcare, cat. no. NA931V) diluted 1:3,000 in TBST / 2% dry milk. Signals were quantified
using ImageJ software.
Fluorescence spectra
Samples of recombinant GFP at 0.5 µM in PBS were mixed with either buffer or 10 µM of a LaG
protein. Fluorescence spectra were obtained on a Synergy Neo microplate reader (BioTek).
Excitation spectra from 300 nm to 530 nm were taken at an emission wavelength of 560 nm, and
emission spectra were measured from 450 nm to 600 nm at an excitation wavelength of 425 nm.
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Phylogenetic analysis
Phylogenetic trees and alignments were generated from LaG amino acid sequences using the
Phylogeny.fr web service (Dereeper et al., 2008; Dereeper et al., 2010).
Mapping of nanobody binding epitopes on GFP by NMR
Three variants of GFP were used in the preparation of NMR samples. GFP-His 6 (eGFP), the
variant used for immunization; GFPuv, the variant for which backbone

15

N-1H chemical shift

assignments were available from BMRB file 5666 (Khan et al., 2003) and a crystal structure was
available from PBD ID 1B9C (Battistutta et al., 2000); GFPuv_A206K (GFPuv_M), a monomeric
version of GFPuv (Zacharias et al., 2002).
All NMR samples contained between 500 and 20 µM 15N-GFP either alone or in the presence of
a 1-1.2 molar excess of LaG, 10mM sodium phosphate buffer, pH 7.4, 150mM NaCl and 90%
H 2 O/10% D 2 O. All NMR spectra (2D 1H-15N HSQC) were measured at 310K on a Bruker Avance
DPX-600 MHz spectrometer equipped with a TCI cryoprobe. NMR experiments and analysis
were performed by Ilona Nudelman.
Backbone 1H-15N assignments of GFPuv were obtained from a comparison between a 1H-15N
HSQC spectrum of GFPuv alone and a simulated 1H-15N HSQC based on BMRB 5666 (Khan et
al., 2003). Due to a very high similarity between the two, 1H-15N backbone assignment of GFPuv
was obtained for 97% of 1H-15N backbone resonances for which assignment was available in
BMRB5666. The accuracy of the GFPuv assignment was verified by mapping the binding site of
a previously identified nanobody, GFP-Trap, on GFPuv. The crystal structure of the GFP/GFPTrap complex is available in the PDB (PDB ID 3K1K)(Kirchhofer et al., 2010) and a comparison
between the X-ray crystallography-derived binding site (obtained by analysis of 3K1K by PISA -
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'Protein interfaces, surfaces and assemblies' service at the European Bioinformatics Institute
(http://www.ebi.ac.uk/pdbe/prot_int/pistart.html) (Krissinel and Henrick, 2007)) and the one
determined by the chemical shift perturbation method, reveals they overlap, thereby confirming
our assignment of GFPuv residues.
Backbone 1H-15N assignments of GFPuv_M were obtained from a comparison between a 1H-15N
HSQC spectrum of GFPuv and that of GFPuv_M. Assignment was verified by mapping the
dimerization site of GFPuv and comparing it to the crystal structure of PDB ID 1B9C(Battistutta
et al., 2000) (analyzed for interacting residues using PISA(Krissinel and Henrick, 2007)).
All chemical shift differences were calculated using equation (1) where CSD is the total

 ∆δN 
2
 + ∆δH

5 
CSD = 
2
(1)
2

chemical shift difference and ∆δN and ∆δH are the chemical shift differences in the free and bound
states between the amide nitrogens and protons, respectively. The CSD cutoff for binding site
residues was 0.05ppm for GFP-Trap binding site and for GFPuv dimerization site and 0.03ppm
for all LaG binding sites.

mRNP purifications
Cloning
The MET3 promoter was subcloned from p404MET3 into pRS414 (from N. Buchler and F. Cross)
using SacI and SpeI restriction sites to create pRS414-MET3. HA-MS2(ΔFG)-eGFP-SV40NLS
was PCR-amplified from pMS2-GFP (Fusco et al., 2003) and cloned into pRS414-MET3 to create
pRS414-MET3-MS2CP-GFP. Wild-type eGFP and mCherry sequences were PCR-amplified and
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cloned into pRS426-TDH3 (Mumberg et al., 1995) using SpeI and XmaI restriction sites. Four
repeats of the MS2 hairpin were inserted after these sequences between XmaI and XhoI sites, using
complementary primers: 5’- ccgggCCTAATTGCCTAGAAAACATGAGGATCACCCATGT
CTGCAGGTCGACTCTAGAAAACATGAGGATCACCCATGTCTGCAGGTCGACTCTAGA
AAACATGAGGATCACCCATGTCTGCAGGTCGACTCTAGAAAACATGAGGATCACCC
ATGTCTGCAGTATTCc-3’ and 5’-tcgagGAATACTGCAGACATGGGTGATCCTCATGTTT
TCTAGAGTCGACCTGCAGACATGGGTGATCCTCATGTTTTCTAGAGTCGACCTGCAG
ACATGGGTGATCCTCATGTTTTCTAGAGTCGACCTGCAGACATGGGTGATCCTCATG
TTTTCTAGGCAATTAGGc-3’.
ACT1 and RPS30b intron sequences were amplified from yeast w303 genomic DNA, and then
blunt-end ligated into pRS426-mCherry-4xMS2 and pRS426-mCherry plasmids digested with
MscI. HSP26 and GLC3 promoters were PCR amplified from yeast genomic. A 2x repeat
sequence of Rap1p binding sites (5’GTGGTGCACAGATGTAACGTTCCAAAATGTATG
GATGGTA-3’) was synthesized and inserted immediately upstream of the TDH3 promoter. These
promoters were subcloned into the pRS426-mCherry and pRS426-mCherry-4xMS2 plasmids
using SacI and SpeI restriction sites. Finally, ASH1 and CTH2 3’ UTR sequences were amplified
from yeast genomic DNA and subcloned into pRS426-mCherry and pRS426-mCherry-4xMS2
plasmids after the 4xMS2 tag using XhoI and EagI restriction sites.
Strains
Strains used in this work were derived from wild-type W303 (MATa ade2-1 ura3-1 his3-11,15
trp1-1 leu2-3,112 can1-100). NAB2, CBP80, CDC33, and THP2 were genomically tagged at the
C-terminus using a PPX-Protein A::HIS5 cassette (Rout et al., 2000).

The PPX sequence

(GLEVLFQGPS) is the target of human rhinovirus 3C protease. For sequential RNA purifications,
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pRS414-MS2CP-GFP was transformed into the appropriate strain, followed by transformation
with the transcript-encoding pRS426 plasmid. Transformations were performed using standard
lithium acetate techniques. Cells were grown at 30°C in complete synthetic defined medium
lacking L-tryptophan, uracil, and L-methionine.
Sequential RNA affinity purifications
Yeast cells were grown, harvested at mid-log phase and cryogenically milled as previously
described (Alber et al., 2007; Oeffinger et al., 2007). 2 g of frozen cell powder was resuspended
in 8 ml of RNP buffer (20 mM HEPES, pH 7.4; 150 mM NaCl; 110 mM K-acetate; 1 mM DTT;
0.1% Tween 20; 0.5% Triton X-100; 1:5000 RNasin (Promega); 1:5000 Antifoam B; 1 mM PMSF;
3 µg/ml pepstatin A). Lysate was spun at 10,000 x g for 10 min., and the supernatant incubated
with a 200 µl suspension (30 mg beads) of IgG-conjugated Dynabeads equilibrated in RNP buffer
(Thermo Fisher). After a 30 min. incubation at 4°C, beads were washed 3 times with 1 ml RNP
buffer, and resuspended in 150 µl RNP with 80 ng/µl PreScission Plus protease. This was
incubated for 1 hr at 4°C, and the supernatant was collected. This was pooled with an additional
75 µl RNP wash of the beads, and the combined solution was incubated for 30 min with a 10 µl
suspension (1.5 mg beads) of Dynabeads conjugated to LaG16-G 4 S-LaG2 nanobody. After 3
washes with RNP buffer, protein was eluted at 72°C for 10 min. with 25 µl NuPAGE LDS buffer.
When prepared for MS analysis, this elution was reduced for 10 min. at 72°C with 25 mM DTT,
then alkylated with 0.1 M iodoacetamide for 30 min. at room temperature. For RNA isolation,
beads were instead resuspended in 600 µl RLT buffer for RNeasy purification (Qiagen).
To determine yields, samples of resuspended lysate were taken before and after each binding step.
These were run on a 4-12% Novex Bis-Tris gel in MES running buffer (Thermo Fisher), and
probed by Western blotting using, for GFP, mouse anti-GFP antibody (Roche, cat. no. 11 814 460
126

001) diluted 1:1,000 in TBST / 2% dry milk and an anti-mouse, HRP-conjugated secondary (GE
Healthcare, cat. no. NA931V) diluted 1:3,000 in TBST / 2% dry milk. For PrA, membranes were
instead probed with peroxidase anti-peroxidase (Sigma, cat. No. P1291) diluted 1:5,000 in TBST.
Signals were quantified using ImageJ software.
Mass spectrometry-based proteomic analysis
Alkylated affinity isolation elutions were purified as single gel plugs by SDS-PAGE: samples were
run at 125 V for 7 min. on a 10% Bis-Tris gel (Thermo Fisher), which was then stained with
Coomassie Blue dye. Bands were then excised as a single piece, destained, and dehydrated. Ingel digestion with trypsin was performed on destained dehydrated gel pieces overnight with 0.5-1
µg trypsin in 50 µl 50 mM ammonium bicarbonate (ABC) buffer with 10% acetonitrile (ACN).
Tryptic peptides were extracted with POROS20 C18 beads (Krutchinsky et al., 2001), desalted on
Zip Tips (0.6 µl C18 resin, Millipore), sequentially eluted with 40% and then 90% acetonitrile /
0.1% acetic acid, and the eluates pooled, concentrated by vacuum centrifugation, and suspended
in 10 µl of 0.1% formic acid (FA). Desalted peptides (2 µl) were analyzed by direct injection onto
a C 18 analytical column (EASY-Spray 3 µm, 150 mm x 0.075 mm) using a Thermo EASY-nLC
100 nanoLC coupled online to an Orbitrap Q Exactive Plus (QE+) or Fusion mass spectrometer
(Thermo Fisher). Peptide separation and MS detection was performed over 60 min at ~300 nl/min
using a discontinuous ACN gradient from 0 to 30 % mobile phase B over 60 min, followed by 30
to 100% B over 15 min (mobile phase A, 0.1% FA; mobile phase B, 97% ACN in 0.1% FA). The
spray voltage was set at 1.9–2.3 kV. The instruments were operated in the data-dependent mode,
in which the most abundant ions were fragmented by higher-energy collisional dissociation (HCD)
(HCD collision energy 30 (QE+) or 35 (Fusion)), and analyzed in the Orbitrap mass analyzer. The
target resolution for MS1 was 70,000 (QE+) and 120,000 (Fusion), and for MS2 was 17,500 (QE+)
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and 30,000 (Fusion). Ions (300–1,700 m/z QE+, 400-1500 m/z Fusion) with a charge state of >1
were selected for fragmentation. A dynamic exclusion of 10 s (QE+) and 30 s (Fusion) and a 'lock
mass' at 371.1012 Da were used.
Mass spectrometry data processing and quantitation
Combined MS/MS spectra were extracted from Thermo RAW files derived from three biological
replicate samples, and searched by Proteome Discoverer/SEQUEST (version 2.0/2.1, Thermo
Fisher) against a Saccharomyces cerevisiae protein sequence database and a common
contaminants database. SEQUEST search parameters were as follows: full trypsin specificity with
2 missed cleavages, precursor and fragment tolerances of 20 ppm and 0.6 Da, fixed modification
of carbamidomethylation of cysteine, and variable modification for methionine oxidation. Putative
SEQUEST peptide-spectrum matches (PSMs) were scored by the Percolator algorithm (Spivak et
al., 2009) to assign individual expectation scores (PEP). PSMs were filtered to achieve an
estimated 1% peptide false discovery rate (q-value < 0.01) and then PSMs were assembled into
protein groups using the “strict maximum parsimony principle” option. Relative label-free
quantitation was performed using the Proteome Discoverer precursor ions area quantification
workflow on the top 3 most intense peptides per protein. Results were exported to Excel for
downstream analysis. Abundances for the three biological replicates were averaged. Proteins with
fewer than three peptides were not analyzed.
RNA-Seq and real-time PCR
RNA from sequential affinity purifications was purified using the RNeasy kit (Qiagen). RNA was
fragmented and ligated to adaptors before library preparation using Illumina kits, and run on a
HiSeq 2500 sequencer with 50 bp single reads.
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For qRT-PCR, RNA was reverse transcribed using SuperScript VILO (Thermo Fisher). Real-time
PCR was then with using PowerUp SYBR Green mix (Thermo Fisher) on a QuantStudio 12K Flex
system using standard conditions (Thermo Fisher). The following primer pairs were used to
quantify each gene: mCherry, AGATCAAGCAGAGGCTGAAGCTGA and TGTGGGAGG
TGATGTCCAACTTGA; GFP, TGGTGTTCAATGTTTTGCGAG and GCTCTGGTCTTGT
AGTTACCG; 18S rRNA, GAGTCCTTGTGGCTCTTGGC and AATACTGATGCCCCCGACC
(Merz et al., 2008).
Northern hybridization
RNA samples were separated on a 6% TBE-Urea acrylamide gel, and Northern blotting was
performed as previously described (Tollervey, 1987). Briefly, gels were electrotransferred to
Hybond N+ (GE Healthcare), and hybridized at 37°C overnight with probe diluted in a buffer of
50% formamide, 5x SSPE, 5x Denhardt’s buffer, 0.2 mg/ml fish sperm DNA, and 0.2% SDS.
Blots were then washed twice for 15 min. at 42°C with 6xSSPE before being exposed to a
Phosphorimager screen. The following DNA oligomers were end-labeled with [γ-32P]-ATP and
used

as

probes:

mCherry,

TGTGGGAGGTGATGTCCAACTTGA;

GACATGCATGGCTTAATCTTTGAGAC.
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18S

rRNA,

Appendix: Improving and extending the nanobody pipeline
Improvements to the nanobody discovery pipeline
Our initial efforts to development a new method for identifying nanobodies were based on GFP
and mCherry antigens (Fridy et al., 2014). As the GFP tag in particular is a key part of our mRNP
isolation protocol, and mCherry nanobodies could be used as an important control (Chapter 4),
nanobodies against these targets were of the greatest practical interest to our lab. Given the success
of this first application of our new approach, we have since sought to apply it to other antigens of
biomedical interest, taking advantage of the relative ease and flexibility of the approach. In the
process of producing nanobodies against new antigens, we have also made a variety of
improvements in the methodology, allowing more reliable identification of nanobody repertoires
against many antigens at once.
After GFP and mCherry, we first aimed to target three human proteins of biomedical interest:
CTLA4, EPHA2, and dysferlin. CTLA4 is a T-cell receptor that inhibits the activation of cytotoxic
T-cells; inhibition of CTLA4 thus enhances T-cell activation, and an inhibitory antibody,
ipilimumab, has in fact been shown to promote anti-tumor immune responses in clinical trials of
cancer patients (Leach et al., 1996; Hodi et al., 2010). Similarly, ephrin receptor A2 (EPHA2) has
been implicated as a key oncogene in certain cancers, and inhibition of this receptor has been
shown to suppress tumor growth (Oricchio et al., 2011; Udayakumar et al., 2011). The current use
of monoclonal antibodies in these cancer therapeutic approaches is hindered by both high cost (e.g.
$120,000 per course of ipilimumab treatment), and the difficulties of delivery into dense tumors
(Couzin-Frankel, 2013; Maleki et al., 2013). Smaller and less complex nanobodies are expected
to avoid some of these issues, and in fact a number of nanobodies are showing success as
therapeutic agents (Van Bockstaele et al., 2009; Roovers et al., 2011).
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Beyond these two cancer targets, we are also attempting to generate nanobody reagents against
dysferlin. Mutations in this gene are associated with multiple forms of muscular dystrophy, such
as Miyoshi myopathy and limb girdle muscular dystrophy (Barthelemy et al., 2011). The dysferlin
protein is a very large (~240 kDa) transmembrane protein highly enriched in muscle cells; its
functions are not fully understood, but it appears to play an important role in membrane
maintenance and muscle repair. Due to its involvement in disease and the many questions related
to its function, reagents able to target dysferlin’s many domains have long been sought. To date,
very few antibodies have been generated against dysferlin, possibly due to the difficulties in
producing stable protein and subsequently raising a response against this structurally and
proteolytically unstable target. We therefore aimed to generate a large repertoire of nanobodies
against dysferlin, with the goal of improving the reagents available for research and diagnostic
purposes. While some efforts have been made to produce nanobodies against dysferlin, so far only
two clones have been generated using traditional phage display approaches (Huang et al., 2005).
We immunized animals with these three antigens, as part of a mixture with four other proteins of
interest to collaborators. It has been reported that up to five antigens can be simultaneously
injected into an animal with no adverse effect on the immune response, and informal accounts
suggest that responses can even be generated against dozens of proteins at once (Pardon et al.,
2014). This is perhaps not surprising, as animals in the wild are expected to be exposed to many
natural invaders at once, each presenting multiple antigens, and must be able to mount
simultaneous immune responses. As with GFP and mCherry, we immunized three llamas, but also
injected two alpacas with dysferlin-GFP. It was reasoned that the smaller size of alpacas to llamas
could result in a relatively stronger immune response to the same antigen dose, and other groups
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have successfully generated nanobodies from alpacas with no changes in protocol (Rothbauer et
al., 2006; Maass et al., 2007).
Overcoming the limitations of papain digestion
Sera from immunized animals showed strong activity against EPHA2, CTLA4, and dysferlin, and
V H H fractions and V H H sequencing data was obtained as before from sera and bone marrow
samples. However, in contrast to GFP and mCherry, we found that after affinity purification of
antigen-specific V H H IgG, the papain digest used to release Fc fragments unavoidably led to
complete proteolysis of immobilized EPHA2 and dysferlin. It is well established that papain
cleaves polypeptides with very broad specificity, with only moderate preference for bulky
hydrophobic residues at one amino acid position in its active site (Kimmel and Smith, 1954;
Schechter and Berger, 1967). With careful titration however, papain preferentially targets the IgG
hinge region, and has long been the standard protease used to cleave IgG into Fab and Fc fragments
(Porter, 1959; Nisonoff et al., 1960; Parham, 1983). With GFP and mCherry, two highly stable
and compact beta-barrel proteins (Ormo et al., 1996; Yarbrough et al., 2001), bound V H H IgG
could be readily digested with papain to release Fc, in easily optimized conditions in which the
immobilized antigen was not degraded. With less stable proteins however, it became clear that no
digest conditions are available that allowed sufficient cleavage of IgG while avoiding excessive
proteolysis of the antigen. With the antigen degraded, no specific V H H binders can remain on the
resin to be analyzed.
To address this papain digestion problem, we first attempted to avoid the papain digestion step
entirely. In theory, this should leave intact IgG on the antigen resin, complete with both Fab and
Fc regions.

When performing MS on these samples to identify nanobody candidates, the

remaining highly conserved Fc region was expected to give abundant extraneous peptides that
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could overwhelm detection of more diverse peptides from the V H H region, but with sufficient
sensitivity, we anticipated adequate identification of the informative peptides.

However,

performing these non-digest purifications with anti-GFP V H H as a control, we consistently found
that while positive candidates could be detected, the candidate list had far more non-specific clones
throughout, making it difficult to identify positives without impractically extensive screening
(Figure A.1). The reason for this increase in non-specific hits is unclear, but is presumably due to
complications from additional peptides from either Fc domains, or from non-specific V H H regions
that are no longer washed away as efficiently from the resin; as papain is no longer separating IgG
molecules into monovalent variable domains, it is possible that the higher avidity of bivalent
antibodies allows very weak binders to be retained. It is also possible that sets of “sticky” nonspecific V H H binders always tend to associate with the antigen resin, but that papain could
destabilize these by partial proteolysis, causing them to dissociate.
Due to the disadvantages of both papain and complete omission of digestion, we sought an
alternative protease to achieve more specific IgG cleavage. A variety of papain alternatives have
been suggested to offer more specific digestion of IgG hinge regions, including lysyl
endopeptidase, V8 protease, or ficin (Mariani et al., 1991; Yamaguchi et al., 1995). More recently
though, a protease with strong site specificity for a sequence found in certain IgG hinges was
identified from S. pyogenes, known as IdeS (von Pawel-Rammingen et al., 2002). While this
enzyme does not recognize every IgG subtype, it has no known non-IgG substrates, avoiding the
risk of off target proteolysis in our method. Upon testing commercially available IdeS on llama
V H H fractions, we found that more than 90% of IgG was specifically cleaved, with no overdigestion observed (with Junjie Wang, B. Chait lab) (Figure A.2a). Additionally, no other proteins
or antigens we tested were cleaved by IdeS, in stark contrast to papain (Figure A.2b). We next

133

200
180

Overall Rank

160
140

No digestion
IdeS band 1
IdeS band 2
IdeS band 3
Papain

120
100
80
60
40
20
0

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

No. of identified LaGs
Figure A.1. Identification of verified anti-GFP nanobodies with papain, IdeS, or no digestion. VHH
affinity-purified over GFP resin was digested in different ways before MS analysis to identify
nanobody candidates. The resulting candidate lists were searched for the 26 verified LaG nanobody
sequences. The overall number of candidates searched (y-axis) was then plotted against the
corresponding number of LaGs identified (x-axis).

134

Figure A.2. Efficient and specific IgG digestion by IdeS. (a) A V H H IgG fraction was purified
over GFP sepharose, then digested on resin with IdeS. Input, flow-through (FT) and ammonium
hydroxide elutions were analyzed by SDS-PAGE. Fc fragments were found at the predicted MW
of 30-32 kDa, and VHH fragments at 15-25 kDa. Variation in Fc and V H H sizes are consistent
with short (IgG3) versus long (IgG2) hinge variants (Hamers-Casterman et al., 1993). Bands
corresponding to long hinge (1) and short hinge (2 and 3) V H H were analyzed by MS (Figure 3.1).
(b) IgG, GFP, bovine serum albumin (BSA), and yeast alcohol dehydrogenase (ADH) were
digested with 0, 50, or 500 ng of papain, or 67 units of IdeS. All proteins were sensitive to papain,
while only IgG was cleaved by IdeS.
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tested IdeS-digested antigen-specific V H H by MS. Using GFP as a control antigen, we saw far
fewer non-specific sequences in the resulting candidate lists when compared to non-digested
samples. Confirmed GFP-binding sequences thus tended to rank much more highly, similar to our
original papain results (Figure A.1).
As we were able to recapitulate our original papain results for GFP using IdeS, we have now
reanalyzed IdeS-digested samples for the previously problematic CTLA4, EPHA2, and dysferlin
antigens. With this new approach, we have successful identified many nanobody candidates, with
positive hit rates averaging approximately 50% (Figure A.3). We are now determining the binding
characteristics of these nanobodies, and in the case of CTLA4 and EPHA2 nanobodies, providing
them to collaborators to assess in vivo inhibitory function.
Nanobodies targeting Protein A
In the course of generating nanobody repertoires against various antigens, we observed that
approximately half of identified nanobody clones bound robustly to Protein A (PrA), consistent
with previous studies, but somewhat counterintuitive given PrA’s more commonly known affinity
for IgG Fc domains (Frenken et al., 2000; Fridy et al., 2014). PrA and its derivatives continue to
be widely used biological tools, due to their high affinity for the Fc domain of many antibodies. It
is a commonly used protein tag, with multiple copies of its five homologous antibody-binding
domains often used to increase overall avidity to IgG binding partners (Uhlen et al., 1983; Rigaut
et al., 1999). Curiously, in addition to its well-known affinity for the Fc region, PrA has been
found to bind certain immunoglobulins through their Fab domains using a distinct binding
mechanism (Sasso et al., 1991; Jansson et al., 1998). It has similarly been observed that
recombinant nanobodies, which are derived from camelid heavy chain-only V H H antibody
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Figure A.3. Verification of nanobody candidates against CTLA4 and EPHA2.
Llama
antibodies against CTLA4 (LaCs) or EPHA2 (LaEs) were expressed in E. coli, and lysates were
incubated with the corresponding antigen immobilized to sepharose resin, washed and
eluted.
Input (I), flow-through (F), and SDS elutions (E) were analyzed by SDS-PAGE. Five
LaCs and four LaEs were found in elutions (red arrows), indicating positive antigen binding.
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variants, can sometimes bind PrA through their Fab-like single variable domain (Frenken et al.,
2000).
To date, standard purified IgG protein has been the reagent of choice for isolating PrA-tagged
complexes (Lindmark et al., 1983; Moks et al., 1986), recently supplemented by an engineered
high affinity affibody (Lindborg et al., 2013).

However, the heterogeneous nature of IgG

preparations, high molecular weight, lot-to-lot variation, and cost make these less than ideal for
many applications, particularly in proteomics. Additionally, we have found that any particular
recombinant protein used for affinity binding of a single target can display unpredictable off-target
binding in certain systems, making it valuable to have more than one available option (Fridy et al.,
2014). Given the well-established ease of use and versatility of nanobodies, we sought to generate
such a reagent with high affinity for PrA.
When assessing the repertoire of nanobodies that we had previously identified, sequence
alignments of PrA binders revealed highly conserved framework regions. These sequences all
contained CDR loops specific for their original antigen, however, and to generate a nanobody with
no extraneous binding activity, we synthesized four sequence variants derived from these
consensus sequences with designed minimal or absent CDR loops (Figure A.4a). Once synthesized
and expressed in E. coli with a periplasmic leader sequence, all four proteins (termed llama
antibody against Protein A, or LaP 1-4) showed high levels of expression, and high solubility after
periplasmic purification. These crude periplasm preparations were incubated with PrA-Sepharose,
and all constructs displayed high affinity, particular LaP-1, which was selected for follow-up
studies. In all cases, no detectable binding was observed for the original antigen (data not shown).
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Figure A.4. Design and characterization of PrA nanobodies. (a) Highly conserved regions from
multiple identified nanobody sequences were used as a framework for four engineered nanobodies
against PrA (LaP-1-4), with varying minimal linkers used in place of existing CDR regions.
Asterisks: residues whose mutation eliminates PrA binding. (b) SPR sensorgrams are shown for
injections of multiple concentrations of 2xLaP-1 nanobody over immobilized 4xPrA. Curves fit
from a Langmuir model are shown in black. (c) Binding constants determined by SPR for either
LaP-1 nanobody or 2xLaP-1 dimerized nanobody against immobilized 1xPrA, 2xPrA, or 4xPrA.
Corresponding association rates (ka), dissociation rates (kd), and dissociation constants (Kd) are
shown.

140

Surface plasmon resonance (SPR) analysis was performed to determine the binding kinetics of
LaP-1’s interactions with multiple recombinant PrA constructs, containing 1, 2, or 4 repeats of the
IgG-binding domain (Figure A.4c). Regardless of the number of PrA repeats, LaP-1 bound these
proteins with a K D of 70-120 nM. While suitable for many applications, it was reasoned that this
affinity could be increased by generating a homodimeric form of the nanobody. Two copies of the
LaP-1 sequence were therefore fused using a glycine-rich peptide linker (3 repeats of GGGGS).
As the LaP-1 monomer is only 13 kDa, even this dimerized form remains a relatively small 27
kDa. After purification, the PrA affinities of this 2xLaP-1 fusion protein were similarly assessed
by SPR (Figure A.4b,c). When binding to 2xPrA or 4xPrA constructs, the affinity of the dimer
was more than 300-fold stronger than the LaP-1 monomer, with a K D of 360-370 pM.
Given the structural similarity of the nanobody variable region to other mammalian Fab fragments,
it was hypothesized that the LaP-1 nanobodies interacted with PrA through an analogous binding
surface, rather than an Fc-like binding mechanism (Desmyter et al., 1996; Jansson et al., 1998).
To test this, mutagenesis was done across the homologous sequences corresponding to this binding
region (Figure A.5a) (Graille et al., 2000). Mutations in two residues, R21 and N85, eliminated
PrA binding. These are both present in the homologous binding region, and expected to be
necessary for PrA binding via an Fab-like interaction. A model of the proposed PrA:LaP-1
interaction was also generated via homology to a PrA:Fab crystal structure (PDB ID: 1DEE)
(Graille et al., 2000) using the program I-TASSER (Zhang, 2008; Roy et al., 2010; Roy et al.,
2012), and is consistent with the mutagenesis results (Figure A.5b).
To investigate the specificity and versatility of these anti-PrA nanobodies, we assessed their
effectiveness in ex vivo affinity isolations of PrA-tagged protein complexes from yeast and
bacteria. LaP-1 and 2xLaP-1 proteins were conjugated to magnetic beads and used to isolate tagged
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Figure A.5. Mapping of PrA:LaP-1 binding interface. (a) LaP-1 nanobodies with the designated
point mutant were expressed in bacteria, and periplasmic extracts were incubated with
PrA-Sepharose. For each mutant, input (I), flow-through (F), and elution (E) samples from the
Sepharose binding were run by SDS-PAGE and Coomassie-stained. (b) The PrA:LaP-1
interaction was modeled using I-TASSER, via LaP-1’s homology to Fab in a PrA:Fab crystal
structure (PDB ID: 1DEE). The structure was visualized in PyMOL. Grey: LaP-1; Beige: PrA;
Red: R21 and N85 residues, which are required for PrA binding.
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RNA polymerase from E. coli (Westblade et al., 2008), the S. cerevisiae Nup84 subcomplex of the
nuclear pore complex (NPC) (Brohawn et al., 2009; Fernandez-Martinez et al., 2012) and mRNA
cytoplasmic cap binding complex (Goyer et al., 1989) (Figure A.6a). In all cases, both the
monomeric and dimeric LaP-1 proteins were able to efficiently isolate the targeted complex with
yield and purity comparable to control affinity isolations with polyclonal IgG, and negligible nonspecific binding or contamination. The tandem affinity purification (TAP) tag is a frequently used
PrA alternative, containing two artificial PrA Z domains (Rigaut et al., 1999). However, consistent
with other studies showing weak binding between this Z domain and Fab fragments (Ljungberg et
al., 1993; Jansson et al., 1998), our LaP-1 proteins are only able to recover very limited amounts
of TAP-tagged protein in affinity isolations. The PrA Z domains in the TAP tag have only a single
glycine to alanine point mutation however, so binding should be restored by reverting this
mutation.
In addition to these original LaP-1 proteins, we generated constructs containing an additional free
cysteine at the C-terminus. Thiol chemistry can thus be targeted to the C-terminus, which allowed
us to reversibly immobilize LaP-1 to magnetic amine-coated Dynabeads using an N-Succinimidyl
3-(2-pyridyldithio)-propionate (SPDP) crosslinker with a 12 unit PEG spacer. This produces a
disulfide-containing crosslink to the bead, which is easily cleavable in mild reducing conditions
(Carlsson et al., 1975; Kiefer, 1975). Beads with LaP-1 immobilized in this manner were tested
in isolations of RNA polymerase, Nup84, and Cdc33 as before. Again, yield and purity comparable
to IgG was observed, and by a short incubation with 25 mM DTT, 40-90% of the isolated protein
could be eluted (Figure A.6b). This level of elution efficiency is comparable to that seen in other
native methods of PrA release (Rigaut et al., 1999; LaCava et al., 2013). The complex-to-complex
difference in yield is also a consistent phenomenon, likely due to differences in interactions with
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Figure A.6. Affinity isolations performed with LaP-1 nanobodies. (A) LaP-1, 2xLaP-1, or rabbit
IgG were conjugated to epoxy-activated magnetic beads and used to isolate E. coli RpoC-PrA (an
RNA polymerase subunit), as well as S. cerevisiae Nup84-PrA (an NPC subcomplex component)
and Cdc33-PrA (a protein in the mRNA cytoplasmic cap binding complex). Bands previously
determined by MS are labeled. (B) LaP-1 was reversibly immobilized to magnetic beads using
SPDP crosslinker, and used for affinity isolations as in (A). Bound protein was first eluted in 25
mM DTT (DTT), before release of remaining bound protein in LDS (LDS). The yield of protein
recovered in the DTT elution step, as compared to total eluted protein, is listed with the s.e.m. All
experiments were performed in duplicate.
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the bead surface. This approach does necessarily lead to release of both PrA-associated and
unassociated LaP-1 nanobody in the elution. Due to the small size (13 kDa) of LaP-1 however, an
additional purification step, such as gradient centrifugation, which is often necessary for sensitive
downstream applications like electron microscopy, can easily remove unbound nanobody.
In either monomeric or dimeric form, the LaP-1 nanobody is suitable for highly efficient isolation
of PrA-tagged protein targets. As a small recombinant protein, it is an especially flexible reagent,
as shown in its use in native elutions of protein complexes, making it a convenient option for any
application making use of a PrA-based tag.
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